



Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four *post-hoc* Analyses of Randomized Clinical Trials

Fuwei Liu^{1*†}, Yunhong Wang^{2†}, Jun Luo¹, Lin Huang^{2‡}, Wengen Zhu^{3‡}, Kang Yin^{4*} and Zhengbiao Xue^{4*}

¹ Department of Cardiology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China, ² Department of

Hosptial of Gannan Medical University, Ganzhou, China

Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ³ Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁴ Department of Critial Care Medicine, The First Affiliated

OPEN ACCESS

Edited by:

Antonino Tuttolomondo, University of Palermo, Italy

Reviewed by:

Paolo Calabrò, University of Campania Luigi Vanvitelli, Italy Daniele Pastori, Sapienza University of Rome, Italy

*Correspondence:

Fuwei Liu gzliufuwei@163.com Zhengbiao Xue 57438440@qq.com Kang Yin 474614909@qq.com

[†]These authors have contributed equally to this work [‡]These authors share senior authorship

Specialty section:

This article was submitted to Thrombosis, a section of the journal Frontiers in Cardiovascular Medicine

> Received: 22 December 2021 Accepted: 08 February 2022 Published: 04 March 2022

Citation:

Liu F, Wang Y, Luo J, Huang L, Zhu W, Yin K and Xue Z (2022) Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials. Front. Cardiovasc. Med. 9:841341. doi: 10.3389/fcvm.2022.841341 **Background:** Several studies have investigated the effect of direct oral anticoagulants (DOACs) in Latin American patients with atrial fibrillation (AF), but the results remain controversial. Therefore, we aimed to compare the efficacy and safety of DOACs vs. warfarin in Latin American patients with AF.

Methods: We systematically searched the PubMed and Embase databases until November 2021 for studies that compared the effect of DOACs vs. warfarin in Latin patients with AF. Adjusted hazard ratios (HRs) and 95% Cls were pooled by a random-effects model using an inverse variance method.

Results: Four post-hoc analyses of randomized clinical trials (RCTs) involving 42,411 DOACs and 29,270 warfarin users were included. In Latin American patients with AF, for the effectiveness outcomes, the use of DOACs compared with warfarin was significantly associated with decreased risks of stroke or systemic embolism (SSE) (HR = 0.78; 95%Cl.64–0.96), stroke (HR = 0.75; 95%Cl.57–0.99), hemorrhagic stroke (HR = 0.14; 95%Cl.05–0.36), all-cause death (HR = 0.89; 95% Cl.80–1.00), but not ischemic stroke and cardiovascular death. For the safety outcomes, compared with warfarin, the use of DOACs was associated with reduced risks of major or non-major clinically relevant (NMCR) bleeding (HR = 0.70; 95% Cl.57–0.86), major bleeding (HR = 0.70; 95% CI.53-0.92),intracranial hemorrhage (ICH) (HR = 0.42; 95%Cl.24-0.74), or any bleeding (HR = 0.70;95% Cl.62-0.78), but not gastrointestinal bleeding. In non-Latin American patients with AF, for the effectiveness outcomes, the use of DOACs compared with warfarin was significantly associated with decreased risks of SSE (HR = 0.87; 95%CI.75-1.00), hemorrhagic stroke (HR = 0.41; 95%Cl.28-0.60), cardiovascular death (HR = 0.87; 95% Cl.81-0.94), all-cause death (HR = 0.90; 95% CI.85-0.94). Conversely, the risk of myocardial infarction increased (HR = 1.34; 95% Cl 1.13–1.60), but not ischemic stroke. For the safety outcomes, compared with warfarin, the use of DOACs was associated with reduced risks of major or NMCR bleeding (HR = 0.75; 95%Cl.61–0.92), major bleeding

1

(HR = 0.76; 95%CI.63-0.92), ICH (HR = 0.42; 95%CI.36-0.52), and any bleeding (HR = 0.81; 95% CI.71-0.92), but not gastrointestinal bleeding.

Conclusion: Current pooled data from the four *post-hoc* analyses of RCTs suggested that compared with warfarin, DOACs appeared to have significant reductions in SSE, stroke, hemorrhagic stroke, all-cause death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, but comparable risks of ischemic stroke, cardiovascular death, and gastrointestinal bleeding in Latin American patients with AF. DOACs appeared to have significant reductions in SSE, hemorrhagic stroke, all-cause death, cardiovascular death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, and increased the risk of myocardial infarction, but comparable risks of stroke, ischemic stroke, and gastrointestinal bleeding in non-Latin American patients with AF.

Keywords: atrial fibrillation, direct oral anticoagulants, warfarin, Latin American, meta-analysis

INTRODUCTION

Atrial fibrillation (AF) is the most common arrhythmia in adults. The currently estimated prevalence of AF in adults ranges from 2 to 4%, and a 2.3-fold rise is expected due to the longevity in the general population and the increased screening of patients with previously undiagnosed AF (1). Advanced age is widely regarded as a foremost risk factor, but increasing burden of other comorbidities including hypertension, diabetes mellitus, heart failure, coronary artery disease, chronic kidney disease, obesity, and obstructive sleep apnea also contributes to the higher prevalence of AF. Not only that, many modifiable risk factors are potent contributors to AF development and progression (2). Many cardiovascular and cerebrovascular complications, such as 5-fold rise in stroke and 2 times the risk of mortality, are prevalently screened in patients with AF (3). AF-associated thromboembolic events are lead contributors for the poor prognosis in patients with AF, which involves higher morbidity and mortality (4, 5). Antithrombotic therapy effectively reduces the incidence of embolism in patients with AF. Direct oral anticoagulants (DOACs) have superior effectiveness and safety outcome for the prevention of stroke and thromboembolic events in patients with AF (6). DOACs are recommended as preferred alternatives to warfarin in the American College of Cardiology and/or American Heart Association/Heart Rhythm Society (7) and European Society of Cardiology guidelines (8) due to its superior characteristics in effectiveness, safety, and convenience, especially for elderly patients with acute coronary syndrome or chronic kidney disease (9, 10). Important differences in clinical characteristics, response to treatment, and outcomes of patients with AF distribute to the diverse regions of the world. In Latin America, AF is regarded as a considerable cause of high mortality and disability (11). Although prevalence data is limited, the incidence of AF-related stroke and associated morbidity is increasing in this region (12), and anticoagulation is underused (13). Therefore, patients with AF in Latin America undergo higher risk of death and thromboembolic events due to the aging population and poorly managed risk factors of AF, such as hypertension, diabetes, heart failure, etc. The anticoagulant treatment of patients with AF is particularly significant in Latin America.

Several previously published studies demonstrated that patients with AF in Latin America treated with warfarin had higher adjusted mortality rates and incidence of stroke and/or systemic embolism, intracranial hemorrhage, and lifethreatening or fatal bleeding compared with patients with AF in the rest of the world (ROW) (14). Data regarding the effectiveness and safety outcome of anticoagulation regimens in this region is insufficient. Although several new post-hoc analyses of randomized clinical trials (RCTs) well-examined the association between regions (Latin America vs. non-Latin America) and effectiveness and safety outcomes, even explored the use of individual DOACs compared with warfarin in Latin American patients, the superiority of DOACs therapy is still controversial. Although, a previous meta-analysis included the post-hoc analyses and sub-analyses of DOACs, RCTs identified a non-inferiority of DOACs compared with warfarin in Latin American patients with AF (15). However, the RCTs included in this meta-analysis are outdated. New RCTs have been published in recent years and report more endpoint events and even find different results. Therefore, we aimed to reassess the effectiveness and safety outcomes of DOACs vs. warfarin in Latin American and non-Latin American patients with AF.

METHODS

Literature Retrieval

The two common databases of PubMed and Embase were systematically searched until November 2021 for the available studies using the following search terms: (1) atrial fibrillation (2) non-vitamin K antagonist oral anticoagulants OR direct oral anticoagulants OR dabigatran OR rivaroxaban OR apixaban OR edoxaban, and (3) vitamin K antagonists OR warfarin. The detailed search strategies are shown in **Supplementary Table 1**. In this meta-analysis, we included publications in English.

Inclusion and Exclusion Criteria

We included the *post-hoc* analyses of RCTs focusing on the effectiveness and/or safety of DOACs (dabigatran, rivaroxaban,

apixaban, or edoxaban) compared with warfarin in Latin American patients with non-valvular AF. The effectiveness outcomes included stroke or systemic embolism (SSE), stroke, ischemic stroke, hemorrhagic stroke, ischemic stroke, allcause death, cardiovascular death, and myocardial infarction; whereas the safety outcomes included major bleeding, major or non-major clinically relevant (NMCR) bleeding, intracranial hemorrhage (ICH), gastrointestinal bleeding, and any bleeding. The follow-up time was not restricted. We excluded certain publication types such as reviews, case reports, case series, editorials, letters, and meeting abstracts because they had no sufficient data. Studies with overlapping data were also excluded.

Study Screenings and Data Extraction

Two authors (FW-L and YH-W) independently did the data extraction. We first screened the titles and abstracts of the searched records to select potential studies, and the full text of which was screened in the subsequent phase. Disagreements were resolved through discussion or consultation with the third researcher (WG-Z). Two authors independently collected the following characteristics: the first author and publication year, location, data source, study design, inclusion period, patient age and sex, type or dose of DOACs, follow-up time, effectiveness and safety outcomes, the sample size, and the number of events in the vitamin K antagonist (VKA) or DOAC groups, and adjusted hazard ratios (HRs) and 95% CIs.

Quality Assessment

We used the Newcastle-Ottawa Scale (NOS) to perform the quality assessment for the included studies. The NOS tool had three domains, scored a total of 9 points including the selection of cohorts (4 points), the comparability of cohorts (2 points), and the assessment of the outcome (3 points). In this study, we defined studies with the NOS of < 6 points as low quality (16).

Statistical Analysis

We assessed the consistency across the included studies using the Cochrane Q test and the I² statistic. A P < 0.1 for the Q statistic or I² \geq 50% indicated substantial heterogeneity. We first collected the sample size and the number of events in the warfarin or DOAC groups and calculated their corresponding crude rates of effectiveness and safety outcomes. The comparison results between the warfarin or DOAC groups were expressed as HRs and 95%CIs. Second, we assessed the effectiveness and safety of DOACs vs. warfarin in patients with AF using the adjusted HRs. The adjusted HRs and 95%CIs were converted to the natural logarithms (Ln[HR]) and standard errors, which were pooled by a random-effects model using an inverse variance method.

All statistical analyses were conducted using the Review Manager Version 5.4 (the Nordic Cochrane Center, Rigshospitalet, Denmark). The statistical significance threshold was set at a P < 0.05.

RESULTS

The process of the literature retrieval is presented in **Supplementary Figure 1**. A total of 170 studies were identified

through the electronic searches in the PubMed and Embase databases. According to the predefined criteria, we finally included 4 studies in this meta-analysis (14, 17-19). Table 1 shows the baseline patient characteristics of the included studies. All include studies are hoc RCT and the data sources are from effective anticoagulation with factor Xa next generation atrial fibrillation-thrombolysis in myocardial infarction 48 (ENGAGE AF-TIMI 48) (14), apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial (ARISTOTLE TRIAL) (17), rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF trial) (18), and randomized evaluation of longterm anticoagulant therapy (RE-LY) (19). Latin American includes Argentina Brazil, Chile, Colombia, Mexico, Peru, and Venezuela, and all the remaining countries included in the entire trial were considered to be non-LA countries. In total, 8,965 Latin American patients (5,096 taking DOACs and 3,869 taking warfarin) and 62,716 non-Latin American patients (37,315 taking DOACs and 25,401 taking warfarin) were included in this meta-analysis. All of these included studies had a moderate-to-high quality with the NOS score of >6 points.

Crude Event Rates Between DOACs vs. Warfarin

In Latin American patients with AF, for the effectiveness outcomes shown in **Supplementary Figure 2**, the use of DOACs compared with warfarin was significantly associated with decreased risks of SSE [odds ratio (OR) = 0.79; 95% CI.64–0.99] and hemorrhagic stroke (OR = 0.13; 95% CI.05–0.33), but not stroke (OR = 0.76; 95% CI.54–1.07), ischemic stroke (OR = 1.19; 95% CI.80–1.78), all-cause death (OR = 0.91; 95%CI.78–1.07), and cardiovascular death (OR = 1.00; 95%CI.61–1.67). For the safety outcomes in **Supplementary Figure 3**, compared with warfarin, the use of DOACs was associated with reduced risks of major or NMCR bleeding (OR = 0.72; 95%CI.56–0.94), major bleeding (OR = 0.72; 95% CI.53–0.98), ICH (OR = 0.43; 95% CI.21–0.88), and any bleeding (OR = 0.65; 95% CI.57–0.78), but not gastrointestinal bleeding (OR = 0.65; 95% CI.10–3.99).

For patients treated with anticoagulants in non-Latin American patients with AF, for the effectiveness outcomes in **Supplementary Figure 4**, the use of DOACs compared with warfarin use was significantly associated with decreased risks of SSE (OR = 0.87; 95% CI.76–1.00), hemorrhagic stroke (OR = 0.41; 95% CI.25–0.67), all-cause death (OR = 0.89; 95% CI.84–0.95), cardiovascular death (OR = 0.87; 95% CI.79–0.95), but not stroke (OR = 0.92; 95%CI.69–1.22), ischemic stroke (OR = 1.08; 95% CI.82–1.42). For the safety outcomes in **Supplementary Figure 5**, compared with warfarin use, the use of DOACs was associated with reduced risks of major bleeding (OR = 0.77; 95% CI.62–0.95), ICH (OR = 0.43; 95%CI.35–0.53), and any bleeding (OR = 0.62; 95% CI.43–0.88), but not major or NMCR bleeding (OR = 0.80; 95%CI.61–1.04) and gastrointestinal bleeding (OR = 0.90; 95%CI.78–1.04).

TABLE 1 | Clinical characteristics of the included studies.

	Avezum-2018		Co	orbalán-2018		Bahit-2020	Blumer-2021		
	Latin American	Non-Latin American	Latin American	Non-Latin American	Latin American	Non-Latin American	Latin American	Non-Latin American	
Study design	Post-hoc a	nalysis of RCT	Post-ho	oc analysis of RCT	P	ost-hoc analysis of RCT	Post-hoc ar	nalysis of RCT	
Date source	R	E-LY	ENG	AGE AF-TIMI 48		ARISTOTLE TRIAL	ROCKE	ET AF trial	
DOACs	dab	igatran		edoxaban		apixaban	rivaro	oxaban	
Efficacy outcomes	S	SE		SSE	S	SE	S	SE	
	Ischemi Haemorrha Myocardia	oke c stroke agic stroke al infarction a any cause	All c	Stroke nemic stroke cause death vascular death	All caus	se death	All caus	se death	
Safety outcomes	Major b Intracranial Gastrointest Minor b	leeding bleeding hemorrhage inal bleeding	Major bleeding Major or NMCR bleeding Intracranial hemorrhage Gastrointestinal bleeding Any bleeding		Major bleeding Major or NMCR bleeding Intracranial hemorrhage		Major bleeding, Major or NMCR bleedir Intracranial hemorrhag		
Region	Argentina Brazil Colombia Mexico Peru	All remaining countries included in the entire trial were considered to be non-LA countries	Argentina Brazil Chile Colombia Guatemala Mexico Peru	NA	Argentina, Brazil Chile Colombia Puerto Rico Mexico	North America (USA, Canada) Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Norway, Poland, Romania, Spain, South Africa, Sweden, Turkey, United Kingdom, Ukraine) Asia Pacific (Australia, China, Hong Kong, India, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan	Argentina Brazil Chile Colombia Mexico Peru Venezuela	rest of the world	
Age (years)	71.6	71.5	71.4	70.5	71	69.7	75	72	
Sex (% female)	-	-	40.6	30.3	38.6	34.5	42	39	
No. of AF patients	956	17,157	2,661	18,444	3,486	14,733	1,878	12,386	
BMI	-	-	-	-	29	-	27.8	28.3	
Pattern of atrial fibrillation (%)									
Persistent	70.7	33.2	85.2	73	91.5	83.1	91	79	
Paroxysmal	-	-	14.8	27	8.5	16.9	8	19	
New onset/newly diagnosed	-	-	-	-	-	-	1	2	
CHADS2 score	2.2	2.1	2.9	2.8	2.1	2.1	3.6	3.5	

(Continued)

TABLE 1 | Continued

	Avezum-2018		Co	rbalán-2018		Bahit-2020	Blumer	Blumer-2021	
	Latin American	Non-Latin American	Latin American	Non-Latin American	Latin American	Non-Latin American	Latin American	Non-Latin American	
Comorbidities (%)									
Prior stroke, TIA, or non-CNS embolism	11.5	12.6	29.8	28.1	13.8	17.1	56	55	
Carotid or peripheral artery disease	-	-	-	-	-	-	7	9	
Hypertension	82.3	78.7	95.2	93.4	89.1	87.1	93	90	
Diabetes	-	-	28.5	37.2	-	-	39	40	
Prior MI	-	-	6.4	12.3	9.8	15.2	11	18	
CHF	41.1	31.5	63.4	56.6	38.3	34.8	60	63	
COPD	-	-	-	-	-		7	11	
Medications (%)									
Prior VKA use	44.0	63.0	48.0	60.5	45.8	42.1	61	63	
Prior chronic aspirin use	48.4	39.1	-	-	33.0	30.4	38	36	
ACE inhibitor/ARB	55.9	44.2			-	-	75	74	
Beta-blocker	-	-	59.9	67.2	56.2	64.9	56	66	
Renin, angiotensin, or aldosterone inhibitor	-	-	72.7	64.9	-	-	-	-	
Calcium-channel blockers	-	-	18.4	33.0	-	-	-	-	
Lipid lowering	-	-	28.3	50.6	-	-			
Diuretic agents	-	-	36.7	29	-	-	6.1	59	
Digitalis	-	-	36.7	29	-	-	42	38	
Amiodarone			19.5	10.7	-		14	7	
Follow-up (year)		2.0		2.8		1.8	1.9	9	
Quality assessment	N	DS = 9 points	NC	S = 9 points		NOS = 9 points	NOS = 8	NOS = 8 points	

Liu et al.

AF, atrial fibrillation; RCT, Randomized Controlled Trial; BMI, body mass index; EAST-AFNET 4, Early Treatment of Atrial Fibrillation for Stroke Prevention Trial; RE-LY, Randomized Evaluation of Long-Term Anticoagulant Therapy; ARISTOTLE TRIAL, Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial; ROCKET AF trial, (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SSE, stroke or systemic embolism; major or NMCR bleeding, major or non-major clinically relevant (NMCR) bleeding; CNS, central nervous system; BMI, body mass index; CHF, congestive Heart failure; MI, myocardial infarction; TIA, transient ischemic attack; VKA, vitamin K antagonist; COPD, chronic obstructive pulmonary disease; CHA2DS2-VASc, congestive heart failure/left ventricular ejection fraction <40%, hypertension, age > 75 years (2 points), diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism (2 points), vascular disease, age 65–74 years, female sex; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; NOS, Newcastle-Ottawa Scale.

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% Cl	Hazard Ratio IV, Random, 95% Cl
1.1.1 SSE					
Avezum-2018(110mg DA)	0.086	0.46	4.8%	1.09 [0.44, 2.68]	
Avezum-2018(150mg DA)	-0.616		3.3%	0.54 [0.18, 1.62]	
Bahit-2020(5mg API)	-0.213		24.1%	0.81 [0.54, 1.21]	
Blumer-2021(RIV)	-0.186		20.8%	0.83 [0.54, 1.28]	
Corbalán-2018(30mg EDO)	-0.163	0.2	25.6%	0.85 [0.57, 1.26]	
Corbalán-2018(60mg EDO)	-0.446		21.4%	0.64 [0.42, 0.98]	
Subtotal (95% CI)	-0.440	0.219	100.0%	0.78 [0.64, 0.96]	
	24:2 - 0.00 df - 5 (D -	0.04		0.78 [0.04, 0.90]	•
Heterogeneity: Tau ² = 0.00; 0 Test for overall effect: Z = 2.4	· · · · ·	0.84);	1~ = 0%		
1.1.2 Stroke					
Avezum-2018(110mg DA)	-0.02	0.47	9.2%	0.98 [0.39, 2.46]	_
Avezum-2018(150mg DA)	-1.139		4.6%	0.32 [0.09, 1.17]	
Corbalán-2018(30mg EDO)	-0.151		46.0%	0.86 [0.57, 1.30]	- - -
Corbalán-2018(60mg EDO)	-0.4	0.225	40.1%	0.67 [0.43, 1.04]	
Subtotal (95% CI)		0.45	100.0%	0.75 [0.57, 0.99]	•
Heterogeneity: Tau ² = 0.00; 0 Test for overall effect: Z = 2.0		0.45);	I ^ = 0%		
1.1.3 Ischemic stroke					
	0 700	0 610	7 00/	2 20 10 65 7 401	
Avezum-2018(110mg DA)	0.788		7.0%	2.20 [0.65, 7.40]	
Avezum-2018(150mg DA)	-0.315		4.6%	0.73 [0.16, 3.29]	
Corbalán-2018(30mg EDO)		0.238		1.27 [0.80, 2.02]	
Corbalán-2018(60mg EDO)	-0.051	0.257	40.8%	0.95 [0.57, 1.57]	
Subtotal (95% CI)			100.0%	1.14 [0.83, 1.58]	\mathbf{T}
Heterogeneity: Tau ² = 0.00; 0 Test for overall effect: Z = 0.8		0.54);	I ² = 0%		
1.1.4 Hemorrhagic stroke	0.007	0.0	00.00/	0.44.70.00.0.501	
Corbalán-2018(30mg EDO)	-2.207	0.8		0.11 [0.02, 0.53]	
Corbalán-2018(60mg EDO)	-1.833	0.612		0.16 [0.05, 0.53]	
Subtotal (95% CI)			100.0%	0.14 [0.05, 0.36]	
Heterogeneity: Tau ² = 0.00; 0 Test for overall effect: Z = 4.0		0.71);	l ² = 0%		
1.1.5 Cardiovascular death					
Blumer-2021(RIV)		0.177	30.0%	1.33 [0.94, 1.88]	
Corbalán-2018(30mg EDO)	-0.223	0.139	35.1%	0.80 [0.61, 1.05]	
Corbalán-2018(60mg EDO)	-0.248	0.14	34.9%	0.78 [0.59, 1.03]	• •
Subtotal (95% CI)			100.0%	0.92 [0.68, 1.26]	•
Heterogeneity: Tau² = 0.05; 0 Test for overall effect: Z = 0.5		0.04);	l² = 70%		
1.1.6 All-cause death					
Avezum-2018(110mg DA)	-0.02	0.247	5.5%	0.98 [0.60, 1.59]	-+-
Avezum-2018(150mg DA)	-0.163		5.2%	0.85 [0.52, 1.39]	— +
Bahit-2020(5mg API)	-0.165		27.8%	0.85 [0.69, 1.04]	-
Blumer-2021(RIV)	0.166		15.7%	1.18 [0.89, 1.56]	+
Corbalán-2018(30mg EDO)	-0.236		22.9%	0.79 [0.63, 0.99]	
Corbalán-2018(60mg EDO)					-
,	-0.128	0.115	22.9% 100.0%	0.88 [0.70, 1.10]	▲
Subtotal (95% CI)		0.00		0.89 [0.80, 1.00]	•
Heterogeneity: Tau ² = 0.00; 0 Test for overall effect: Z = 1.9		0.36);	1- = 8%		
					· · · · · · ·
					0.02 0.1 1 10 5

FIGURE 1 | Adjusted effectiveness date of direct oral anticoagulants compared with warfarin in Latin patients with atrial fibrillation. DOACs, direct oral anticoagulants; DA, dabigatran; API, apixaban; EDO, edoxaban; RIV, rivaroxaban; SSE, stroke or systemic embolism; CI, confidence interval.

Adjusted Data of Outcomes Between DOACs vs. Warfarin

In Latin American patients with AF, for the effectiveness outcomes shown in **Figure 1**, the use of DOACs compared with warfarin was significantly associated with decreased risks of SSE

(HR = 0.78; 95% CI.64–0.96), stroke (HR = 0.75; 95%CI.57–0.99), hemorrhagic stroke (HR = 0.14;95%CI.05–0.36), all-cause death (HR = 0.89; 95%CI.80–1.00), but not ischemic stroke (HR = 1.14; 95%CI.83–1.58) and cardiovascular death (HR = 0.92; 95%CI.68–1.26). For the safety outcomes in **Figure 2**,

				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% C	IV, Random, 95% Cl
2.1.1 Major or NMCR bleed	•				_
Bahit-2020(5mg API)	-0.451		23.7%	0.64 [0.50, 0.81]	
Blumer-2021(RIV)	-0.105		25.5%	0.90 [0.73, 1.11]	-
Corbalán-2018(30mg EDO)		0.113	24.7%	0.56 [0.45, 0.70]	• •
Corbalán-2018(60mg EDO)	-0.301	0.102		0.74 [0.61, 0.90]	
Subtotal (95% CI)			100.0%	0.70 [0.57, 0.86]	•
Heterogeneity: Tau ² = 0.03; C Test for overall effect: Z = 3.4		= 0.02)	; l² = 71%		
2.1.2 Major bleeding					
Avezum-2018(110mg DA)	-0.462	0.39	9.4%	0.63 [0.29, 1.35]	
Avezum-2018(150mg DA)	-0.151	0.354	10.7%	0.86 [0.43, 1.72]	
Bahit-2020(5mg API)	-0.504	0.165	22.6%	0.60 [0.44, 0.83]	
Blumer-2021(RIV)	0.157	0.215	18.6%	1.17 [0.77, 1.78]	
Corbalán-2018(30mg EDO)	-0.799	0.221	18.2%	0.45 [0.29, 0.69]	
Corbalán-2018(60mg EDO)	-0.342	0.19	20.5%	0.71 [0.49, 1.03]	
Subtotal (95% CI)			100.0%	0.70 [0.53, 0.92]	•
Heterogeneity: Tau ² = 0.06; 0	Chi ² = 10.89, df = 5 (P	= 0.05)	; l² = 54%		
Test for overall effect: Z = 2.5	54 (P = 0.01)				
2.1.3 Intracranial hemorrha	ge				
Avezum-2018(110mg DA)	-1.661	1.129	5.8%	0.19 [0.02, 1.74]	
Bahit-2020(5mg API)	-0.618	0.347	27.0%	0.54 [0.27, 1.06]	
Blumer-2021(RIV)	-0.02	0.419	23.0%	0.98 [0.43, 2.23]	e
Corbalán-2018(30mg EDO)	-1.309	0.423	22.8%	0.27 [0.12, 0.62]	
Corbalán-2018(60mg EDO)	-1.427	0.448	21.5%	0.24 [0.10, 0.58]	
Subtotal (95% CI)			100.0%	0.42 [0.24, 0.74]	\bullet
Heterogeneity: Tau ² = 0.19; 0 Test for overall effect: Z = 2.9		• 0.10);	l² = 48%		
2.1.4 Gastrointestinal bleed	ling				
Avezum-2018(110mg DA)	-0.431	0.649	12.4%	0.65 [0.18, 2.32]	
Avezum-2018(150mg DA)	0.751	0.492	18.9%	2.12 [0.81, 5.56]	
Corbalán-2018(30mg EDO)	-0.371	0.319	31.8%	0.69 [0.37, 1.29]	_
Corbalán-2018(60mg EDO)	0.285	0.27	36.9%	1.33 [0.78, 2.26]	T
Subtotal (95% CI)			100.0%	1.08 [0.65, 1.78]	-
Heterogeneity: Tau ² = 0.10; C Test for overall effect: Z = 0.3	. ,	: 0.17);	l² = 41%		
2.1.5 Any bleeding					
Avezum-2018(110mg DA)	-0.386	0.153	14.2%	0.68 [0.50, 0.92]	
Avezum-2018(150mg DA)	-0.274	0.148	15.1%	0.76 [0.57, 1.02]	
Corbalán-2018(30mg EDO)	-0.494	0.1	33.2%	0.61 [0.50, 0.74]	+
Corbalán-2018(60mg EDO) Subtotal (95% CI)		0.094	37.5% 100.0%	0.76 [0.63, 0.91] 0.70 [0.62, 0.78]	
Heterogeneity: Tau ² = 0.00; C Test for overall effect: Z = 6.3		: 0.39);	l² = 0%		
					0.02 0.1 1 10 50
					DOACs Warfarin

FIGURE 2 | Adjusted safety date of direct oral anticoagulants compared with warfarin in Latin patients with atrial fibrillation. DOACs, direct oral anticoagulants; DA, dabigatran; API, apixaban; EDO, edoxaban; RIV, rivaroxaban; CI, confidence interval.

3.14 SE Avezum-2018(110mg DA) Avezum-2018(110mg DA) Avezum-2018(Hazard Ratio	Hazard Ratio
Avez.m. 2018 (110mg DA) Avez.m. 2018 (110mg		log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
$\begin{aligned} & \text{Auezum-2018(150mg DA)} & -0.431 0.118 13.1\% 0.65 [0.52, 0.52] \\ & \text{Bahl:2020(fm, AP) Europe } 0.033 0.102 10.1\% 0.055 [0.52, 0.52] \\ & \text{Bahl:2020(fm, AP) North America } 0.282 0.204 7.9% 0.75 [0.51, 1.13] \\ & \text{Buhl:2020(fm, AP) North America } 0.282 0.204 7.9\% 0.75 [0.51, 1.13] \\ & \text{Buhl:2020(fm, AP) North America } 0.282 0.204 7.9\% 0.75 [0.51, 1.13] \\ & \text{Buhl:2020(fm, AP) North America } 0.282 0.204 7.9\% 0.75 [0.51, 1.13] \\ & \text{Buhl:2020(fm, AP) North America } 0.282 0.204 7.9\% 0.75 [0.57, 1.06] \\ & \text{Corbalin-2018(Storg EDO) } 0.064 0.08 15.2\% 0.91 [0.77, 1.08] \\ & \text{Corbalin-2018(Storg EDO) } 0.094 0.066 15.2\% 0.91 [0.77, 1.08] \\ & \text{Hetrogeneity: Tau2 = 0.05, Ch2 = 23.85, df = 7 (P = 0.001); F = 70\% \\ & \text{Test for versall effect: 2 = 1.32 (P = 0.005) \\ & \text{3.1.2 Stroke} \\ & \text{Asceam-2018(110mg DA) } 0.044 0.109 2.42.\% 0.91 [0.74, 1.13] \\ & \text{Asceam-2018(110mg DA) } 0.094 0.096 0.122 24.1\% 0.91 [0.76, 1.08] \\ & \text{Asceam-2018(110mg DA) } 0.086 0.122 24.1\% 0.91 [0.76, 1.08] \\ & \text{Asceam-2018(110mg DA) } 0.086 0.122 24.1\% 0.91 [0.76, 1.08] \\ & \text{Asceam-2018(110mg DA) } 0.288 0.194 2.2\% 0.75 [0.56, 0.97] \\ & \text{Corbalin-2018(00mg EDO) } 0.098 2.60\% 0.100 (0.85, 1.38] \\ & \text{Avezum-2018(110mg DA) } 0.288 0.194 2.2\% 0.75 [0.56, 0.97] \\ & \text{Corbalin-2018(00mg EDO) } 0.038 0.122 2.41.\% 1.09 [0.86, 1.38] \\ & \text{Avezum-2018(150mg DA) } 0.238 0.19 2.6\% 1.10 [0.0\% 1.109 [0.86, 1.38] \\ & \text{Avezum-2018(150mg DA) } 0.238 0.19 2.6\% 1.10 [0.0\% 1.109 [0.86, 1.38] \\ & \text{Avezum-2018(150mg DA) } 0.238 0.19 2.6\% 1.10 [0.0\% 1.109 [0.86, 1.38] \\ & \text{Avezum-2018(150mg DA) } 0.128 0.072 1.0\% \\ & \text{Avezum-2018(150mg DA) } 0.28 0.163 0.3\% 1.135 [1.09, 1.67] \\ & \text{Avezum-2018(150mg DA) } 0.28 0.163 0.3\% 1.35 [1.09, 1.67] \\ & \text{Avezum-2018(150mg DA) } 0.28 0.16 0.33 0.5\% 1.33 [0.75, 1.03] \\ & \text{Avezum-2018(150mg DA) } 0.28 0.163 0.5\% 1.33 [0.75, 1.03] \\ & \text{Avezum-2018(150mg DA) } 0.28 0.163 0.5\% 1.33 [0.75, 1.03] \\ & \text{Avezum-2018(150mg DA) } 0.128 0.078 0.388 (\% 0.88 [0.76, 1.03] \\ & \text{Avezum-2018(150mg DA) } 0.218 0.056 $						
Bahit 2020(Fm API) Excipe and the analysis of the set						
Bahl:2020(Fm, 2AP) Europe -0.039 0.162 10.1% 0.98 [p.70, 1.32] Bahl:2020(Fm, 2AP) North America -0.282 0.204 7.9% 0.75 [p.51, 1.13] Blume-2021(FlV) -0.117 0.091 14.9% 0.88 [p.74, 1.06] Corbalia-2018(Borng EDO) -0.094 0.086 15.2% 0.91 [p.77, 1.08] Corbalia-2018(Borng EDO) -0.094 0.086 15.2% 0.91 [p.77, 1.08] Subtotal (95% Cf) -0.091 0.094 0.109 24.2% 0.91 [p.74, 1.13] Avezum-2018(110mg DA) -0.094 0.109 24.2% 0.91 [p.74, 1.13] Avezum-2018(110mg DA) -0.094 0.092 2.6% 0.91 [p.74, 1.18] Corbalia-2018(00mg EDO) -0.094 0.092 2.6% 0.91 [p.74, 1.18] Corbalia-2018(00mg EDO) -0.094 0.092 2.6% 0.91 [p.74, 1.18] Corbalia-2018(00mg EDO) -0.094 0.092 2.6% 0.91 [p.74, 1.18] Avezum-2018(110mg DA) -0.094 0.092 2.6% 1.43 [1.20, 1.16] Subtotal (95% Cf) -0.094 0.098 2.6% 1.43 [1.20, 1.16] Avezum-2018(110mg DA) -0.288 0.14 22.2% 0.75 [p.58.0.97] Corbalia-2018(00mg EDO) -0.328 0.19 2.6% 1.43 [1.20, 1.71] Corbalia-2018(00mg EDO) -0.348 0.09 2.6% 1.43 [1.20, 1.71] Corbalia-2018(00mg EDO) -0.342 0.22 2.75% 0.33 [p.18, 0.60] Avezum-2018(110mg DA) -1.100 0.307 21.0% 0.33 [p.18, 0.60] Avezum-2018(110mg DA) -1.100 0.307 21.0% 0.33 [p.18, 0.60] Avezum-2018(110mg DA) -1.273 0.322 12.9% 0.28 [p.15, 0.33] Corbalia-2018(00mg EDO) -0.424 0.22 2.75% 0.33 [p.28, 0.66] Corbalia-2018(00mg EDO) -0.424 0.22 2.75% 0.33 [p.28, 0.66] Corbalia-2018(00mg EDO) -0.424 0.22 2.75% 0.33 [p.28, 0.66] Corbalia-2018(00mg EDO) -0.424 0.22 2.75% 0.33 [p.28, 0.64] Heterogeneity: Tau ² = 0.05 Ch ² = 7.12, df = 3 (P = 0.07); P = 58% Tast for overall effect Z = 4.57 (P < 0.00001) 3.1.5 (Cordial-2018(00mg EDO) -0.128 0.078 j. 3.33 [p.10, 1.67] Avezum-2018(110mg DA) -0.128 0.078 j. 3.33 [p.10, 1.67] Avezum-2018(110mg DA) -0.128 0.078 j. 3.33 [p.18, 0.36] Corbalia-2018(00mg EDO) -0.128 0.088 (p.78, 1.03] Corbalia-2018(00mg EDO) -0.128 0.088 (p.78, 1.03] Corbalia-2018						
Bahl: 2020(Sing, AP) Noth America $-0.282 - 0.24 + 7.9\%$ $0.75 [0.51, 1.13]$ Bulmer-2021(RIV) $-0.171 + 0.091 + 1.4\%$ $0.88 [0.74, 1.06]$ Corbalia-2018(Gomg EDO) $-0.094 + 0.086 + 15.7\%$ $1.18 [1.01, 1.38]$ Corbalia-2018(Gomg EDO) $-0.094 + 0.086 + 15.7\%$ $1.18 [1.01, 1.38]$ Corbalia-2018(Gomg EDO) $-0.094 + 0.086 + 15.7\%$ $0.97 [0.77, 1.06]$ Subtotal (95% CI) $-0.094 + 0.094 + 0.092 + 22.3\%$ $0.97 [0.74, 1.13]$ Avezum-2018(150mg EDO) $-0.094 + 0.092 + 22.3\%$ $0.97 [0.74, 1.13]$ Avezum-2018(150mg EDO) $-0.094 + 0.092 + 22.3\%$ $0.91 [0.74, 1.13]$ Avezum-2018(150mg EDO) $-0.094 + 0.092 + 22.3\%$ $0.91 [0.74, 1.13]$ Avezum-2018(150mg EDO) $-0.094 + 0.092 + 22.3\%$ $0.91 [0.75, 1.06]$ Subtotal (95% CI) $100.0046 + 0.192 + 22.41\%$ $1.09 [0.86, 1.38]$ Avezum-2018(110mg DA) $-0.248 + 0.392 + 22.41\%$ $1.09 [0.86, 1.38]$ Avezum-2018(110mg DA) $-0.248 + 0.192 + 22.41\%$ $1.09 [0.86, 1.38]$ Avezum-2018(150mg EDO) $-0.338 + 0.092 + 26.5\%$ $1.43 [1.01, 1.39]$ Corbalia-2018(Gomg EDO) $0.338 + 0.092 + 26.5\%$ $1.43 [1.20, 1.71]$ Fuels for everall effect: $Z = 0.57 (P = 0.0005); P = 82\%$ Test for everall effect: $Z = 0.57 (P = 0.0005); P = 0.0005; P = 83\%$ Test for everall effect: $Z = 0.57 (P = 0.0005); P = 0.0005; P = 0.00$	Bahit-2020(5mg API) Asia Pacific	-0.431	0.178	9.2%	0.65 [0.46, 0.92]	
Blume-2021(R^{1}) - 0.117 0.001 14.9% 0.89 [0.74, 1.06] Corbala-2018($Comg$ EDO) - 0.064 0.086 15.2% 0.91 [0.77, 1.08] Corbala-2018($Comg$ EDO) - 0.094 0.006 15.2% 0.91 [0.77, 1.08] Test for overall effect: Z = 1.92 (P = 0.05): 3.1.2 Stroke Avezum-2018(150mg AD) - 0.094 0.109 24.2% 0.91 [0.74, 1.13] Avezum-2018(150mg AD) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Corbala-2018($Comg$ EDO) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Corbala-2018($Comg$ EDO) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Corbala-2018($Comg$ EDO) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Corbala-2018($Comg$ EDO) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Subtoat (95% CI) - 0.094 0.099 24.2% 0.91 [0.74, 1.13] Avezum-2018($Comg$ EDO) - 0.096 0.099 24.2% 0.91 [0.74, 1.13] Avezum-2018($Comg$ EDO) - 0.098 0.099 24.0% 0.91 [0.72, 1.14] Heterogeneity: Tau ² = 0.04; Ch ² = 16.78, df = 3 (P = 0.0008); P = 82% Test for overall effect: Z = 0.36 (P = 0.39) 3.1.3 Ischemic stroke Avezum-2018($Comg$ EDO) - 0.088 0.09 24.0% 1.00 [0.83, 1.21] Corbala-2018($Comg$ EDO) - 0.088 0.09 24.0% 1.00 [0.83, 1.21] Heterogeneity: Tau ² = 0.06; Ch ² = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018($Comg$ EDO) - 0.444 0.023 27.9% 0.28 [0.15, 0.53] Corbala-2018($Comg$ EDO) - 0.444 0.023 27.9% 0.28 [0.15, 0.53] Avezum-2018($Comg$ EDO) - 0.444 0.023 27.9% 0.28 [0.15, 0.53] Avezum-2018($Comg$ EDO) - 0.444 0.088 1.35% (To 44, 0.08] Corbala-2018($Comg$ EDO) - 0.444 0.088 0.5% 1.35 [1.09, 1.67] Avezum-2018($Comg$ EDO) - 0.451 0.005 36.2% 0.88 [0.76, 1.03] Corbala-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.76, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avezum-2018($Comg$ EDO) - 0.452 0.078 25.2% 0.88 [0.78, 1.03] Avez					0.96 [0.70, 1.32]	
$ \begin{array}{c} Cotalial-2016(Gomg EDO) & 0.666 0.08 15.7\% & 0.91 [0.77, 1.08] \\ Cotalial-2016(Gomg EDO) & 0.094 0.066 15.2\% & 0.91 [0.77, 1.08] \\ Subtotal (95% CI) & 0.07F = 23.65, df = 7 (P = 0.001); P = 70\% \\ Test for overall effect: Z = 1.92 (P = 0.05) & 0.094 0.109 24.2\% & 0.91 [0.74, 1.13] \\ Avezum-2018(110mg DA) & 0.044 0.109 24.2\% & 0.91 [0.74, 1.13] \\ Avezum-2018(100mg EDO) & 0.046 0.069 24.0\% & 0.91 [0.74, 1.13] \\ Avezum-2018(100mg EDO) & 0.046 0.069 24.0\% & 0.91 [0.72, 1.14] \\ Avezum-2018(100mg EDO) & 0.046 0.069 24.0\% & 0.91 [0.72, 1.14] \\ Heterogeneity: Tau' = 0.04; Ch' = 16.78, df = 3 (P = 0.0008); P = 82\% \\ Test for overall effect: Z = 0.36 (P = 0.39) & 0.098 0.048 0.051 (0.72, 0.14] \\ Heterogeneity: Tau' = 0.04; Ch' = 17.65, df = 3 (P = 0.0008); P = 82\% \\ Test for overall effect: Z = 0.36 (P = 0.39) & 0.088 0.042 2.25\% 0.75 (0.88, 0.97) \\ 3.1.3 Ischemic stroke \\ Avezum-2018(100mg DA) & 0.086 0.122 24.1\% & 1.09 [0.86, 1.38] \\ Avezum-2018(100mg EDO) & 0.088 0.09 26.6\% 1.13 [1.20, 1.71] \\ Cotalian-2018(Gomg EDO) & 0.088 0.09 26.6\% 1.13 [1.20, 1.71] \\ Subtotal (95% CI) & 100.0\% & 1.05 [0.81, 1.36] \\ Heterogeneity: Tau' = 0.06; Ch' = 17.65, df = 3 (P = 0.0005); P = 83\% \\ Test for overall effect: Z = 0.37 (P = 0.77) & 0.302 (2.10\% 0.33 [0.18, 0.60] \\ Avezum-2018(100mg DA) & -1.279 0.332 2.19\% & 0.33 [0.18, 0.60] \\ Avezum-2018(100mg DA) & -1.278 0.322 & 19.5\% 0.23 [0.15, 0.53] \\ Cotalian-2018(Comg EDO) & -0.446 0.188 31.2\% & 0.54 [0.44, 0.93] \\ Avezum-2018(150mg DA) & 0.33 0.16 6.95\% & 1.35 [1.09, 1.67] \\ Avezum-2018(150mg DA) & 0.28 0.163 0.35\% 1.33 [0.97, 1.83] \\ Avezum-2018(150mg DA) & 0.28 0.078 0.35\% 1.33 [0.97, 1.83] \\ Avezum-2018(150mg DA) & 0.28 0.078 0.35\% 0.58 (0.78, 0.09] \\ Heterogeneity: Tau' = 0.00; Ch'' = 0.01, df = 1 (P = 0.94); P = 0\% \\ Test for overall effect: Z = -3.28 (P = 0.001) \\ 3.15 Myocardial infarction \\ Avezum-2018(150mg DA) & 0.128 0.068 14.0\% 0.90 [0.79, 1.03] \\ Avezum-2018(150mg DA) & 0.218 0.068 3.85\% 0.88 [0.78, 1.03] \\ Avezum-2018(150mg DA) & 0.128 0.078 3.85\% 0.88 [0.78, 1.03] $	Bahit-2020(5mg API) North America				0.75 [0.51, 1.13]	
Corbain-2018(c0mg EDO) -0.044 0.086 15.2% 0.91 [0.77, 1.08] Heterogeneity: Tau" = 0.03; Ch" = 23.65, df = 7 (P = 0.001); P = 70% Test for overall effect: Z = 1.92 (P = 0.05) 3.1.2 Stroke Avezum-2018(110mg DA) -0.084 0.109 24.2% 0.91 [0.74, 1.13] Avezum-2018(110mg DA) -0.084 0.109 24.2% 0.91 [0.74, 1.13] Corbain-2018(60mg EDO) -0.084 0.092 26.6% 1.18 [10.74, 1.13] Corbain-2018(60mg EDO) -0.094 0.099 20.6% 0.91 [0.76, 1.08] Subtotal (95% CI) -0.094 0.099 20.6% 0.91 [0.76, 1.08] Subtotal (95% CI) -0.094 0.099 20.6% 0.90 [10.76, 1.08] Avezum-2018(110mg DA) -0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(110mg DA) -0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(150mg EDO) 0.358 0.009 26.6% 1.43 [1.20, 1.71] Corbain-2018(60mg EDO) 0.358 0.009 26.6% 1.43 [1.20, 1.71] Corbain-2018(150mg DA) -0.288 0.134 22.2% 0.75 [0.58, 0.97] Corbain-2018(150mg EDO) 0.358 0.009 26.6% 1.43 [1.20, 1.71] Corbain-2018(150mg EDO) 0.358 0.009 26.6% 1.43 [1.20, 1.71] Corbain-2018(150mg EDO) 0.358 0.009 26.6% 1.43 [1.20, 1.71] Corbain-2018(150mg EDO) 0.358 0.009 26.6% 1.00 [0.8.1, 1.36] Heterogeneity: Tau" = 0.00; Ch" = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.14 Hemorrhaptic stroke Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.38 [0.15, 0.53] Corbain-2018(150mg DA) -1.273 0.322 19.9% 0.38 [0.15, 0.53] Corbain-2018(150mg DA) -1.273 0.322 19.9% 0.38 [0.15, 0.53] Corbain-2018(150mg DA) -1.270 0.322 19.9% 0.38 [0.15, 0.53] 3.14 Hemorrhaptic stroke Avezum-2018(150mg DA) -0.28 0.168 31.2% 0.64 [0.44, 0.98] Corbain-2018(150mg DA) -0.28 0.168 30.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) -0.28 0.163 30.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) -0.22 0.073 25.2% 0.88 [0.76, 1.03] Corbain-2018(07mg EDO) -0.151 0.055 36.2% 0.88 [0.76, 1.03] Corbain-2018(07mg EDO) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbain-2018(07mg EDO) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbain-2018(07mg EDO) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbain-2018(07mg EDO) -0.171 0.156 0.056 14.0% 0.90 [0.79,	Blumer-2021(RIV)	-0.117	0.091	14.9%	0.89 [0.74, 1.06]	
Subtal (95% C) 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.87 [0.75, 1.00] 100.0% 0.81 [0.74, 1.13] 100.0% 0.81 [0.72, 1.14] 100.0% 0.81 [0.72, 1.14] 100.0% 0.81 [0.72, 1.14] 100.0% 0.91 [0.72, 1.14] 100.0% 1.92 [0.75, 0.53] 0.97 [0.75 [0.58, 0.97] 0.75 [0.58,	Corbalán-2018(30mg EDO)	0.166	0.08	15.7%	1.18 [1.01, 1.38]	-
Heterogeneity: Tau ² = 0.03; Ch ² = 23.65, df = 7 (P = 0.001); P = 70%. Test for overall effect: Z = 1.92 (P = 0.05) 31.2 Stroke Avezum-2018(110mg DA) -0.094 0.109 24.2% 0.51 [0.74, 1.13] Avezum-2018(110mg DA) -0.094 0.019 24.2% 0.51 [0.74, 1.13] Corbain-2018(00mg EDO) -0.084 0.089 26.6% 1.18 [10.1, 1.39] Corbain-2018(00mg EDO) -0.094 0.089 26.0% 0.091 [0.76, 1.08] Subtol (95% CI) -0.094 0.089 26.0% 0.091 [0.76, 1.08] Avezum-2018(110mg DA) -0.286 0.122 24.1% 0.09 [0.86, 1.38] Avezum-2018(110mg DA) -0.288 0.134 22.2% 0.75 [0.58, 0.97] Corbain-2018(00mg EDO) 0.358 0.09 26.6% 1.43 [1.20, 1.71] Corbain-2018(00mg EDO) 0.358 0.09 26.0% Avezum-2018(110mg DA) -1.273 0.322 19.9% 0.38 [0.59, 0.53] Avezum-2018(110mg DA) -1.273 0.322 19.9% 0.38 [0.59, 0.53] Avezum-2018(10mg DA) -1.27 0.322 19.9% 0.38 [0.59, 0.53] Avezum-2018(10mg DA) -1.22 0.073; P = 58% Test for overall effect: Z = 3.7 (P = 0.007); P = 58% Test for overall effect: Z = 4.37 (P = 0.007); P = 58% Test for overall effect: Z = 4.32 (P = 0.0001) 3.1.5 Myocardial infarction Avezum-2018(10mg DA) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbain-2018(00mg EDO) -0.151 0.085 3.2% 0.86 [0.78, 0.98] Corbain-2018(00mg EDO) -0.151 0.085 3.6.2% 0.86 [0.78, 0.98] Corbain-2018(00mg EDO) -0.151 0.086 7.138, 0.88 (0.78, 0.09] Subtotal (95% CI) -0.000 H = 0.28, 0.47 2.028 3.1.7 All-cause death Biume-Co21(RN) -0.128 0.088 1.4.0% 0.88 [0.78, 1.09] Corbain-2018(00mg EDO) -	Corbalán-2018(60mg EDO)	-0.094	0.086	15.2%	0.91 [0.77, 1.08]	
Test for overall effect: $Z = 1.92$ (P = 0.05) 3.1.2 Stroke Avezum-2018(110mg DA) -0.094 0.109 24.2% 0.91 [0.74, 1.13] Avezum-2018(150mg DD) 0.166 0.082 26.6% 1.181 [1.01, 1.39] Corbalin-2018(60mg EDO) 0.0.094 0.089 26.6% 0.91 [0.75, 1.08] Ocrbalin-2018(60mg EDO) 0.0.094 0.089 26.6% 0.91 [0.75, 1.08] Subtotal (95% CI) Heterogeneity: Tau' = 0.06 (P = 0.39) 3.1.3 Ischemic stroke Avezum-2018(110mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(110mg DA) 0.088 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(10mg EDO) 0.0.098 26.6% 1.43 [1.20, 1.71] Corbalin-2018(60mg EDO) 0.0.098 26.6% 1.00 [0.81, 1.36] Heterogeneity: Tau' = 0.03; CPi = 17.65, df = 3 (P = 0.0005); I ² = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(150mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Corbalin-2018(60mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalin-2018(60mg EDO) -0.944 60.188 12.2% 0.28 [0.15, 0.53] Corbalin-2018(60mg EDO) -0.446 0.18 81.2% Corbalin-2018(60mg EDO) -0.446 0.18 81.2% Corbalin-2018(60mg EDO) -0.446 0.18 81.2% Corbalin-2018(60mg EDO) -0.16 = 7.12, df = 3 (P = 0.07); I ² = 58% Test for overall effect: Z = 4.57 (P < 0.0001) 3.1.5 Myocardial infarction Avezum-2018(150mg DA) 0.23 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.28 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (65% CI) -1.00, Chi ² = 0.01, df = 1 (P = 0.94); I ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.5 Avecance 2018(N) 0.03, 0.168 69.5% 0.38 (0.78, 1.03] Corbalin-2018(60mg EDO) -0.128 0.068 14.0% 0.99 (0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.8% 0.88 [0.78, 1.03] Corbalin-2018(60mg EDO) -0.128 0.068 14.0% 0.99 (0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.99 (0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.99 (0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.98 (0.77,	Subtotal (95% CI)			100.0%	0.87 [0.75, 1.00]	•
3.1.2 Stroke Avezum-2018(110mg DA) -0.094 0.109 24.2% 0.61 (0.74, 1.13) Avezum-2018(150mg DD) -0.044 0.092 26.6% 0.66 (0.52, 0.33) Corbalin-2018(60mg EDO) -0.094 0.099 26.6% 0.01 (0.75, 1.08] Subtotal (95% CI) -0.046 (P = 0.0008); P = 82% Test for overall effect. Z = 0.86 (P = 0.99) 3.1.3 Ischemic stroke Avezum-2018(150mg DA) -0.288 0.132 22.4% 1.09 (0.86, 1.38] Avezum-2018(150mg DA) -0.288 0.132 23.2% 0.75 (0.58, 0.37] Corbalin-2018(60mg EDO) 0.358 0.09 26.6% 1.43 (120, 1.71] Corbalin-2018(60mg EDO) 0.038 0.09 26.6% 1.43 (120, 1.71] Corbalin-2018(60mg EDO) 0.038 0.09 26.6% 1.43 (120, 1.71] Corbalin-2018(60mg EDO) 0.044 0.188 31.2% 0.28 (0.54, 1.36] Avezum-2018(110mg DA) -1.109 0.07 21.0% 0.33 (0.18, 0.60] Avezum-2018(150mg DA) -1.127 0.322 19.9% 0.28 (0.54, 0.53] Corbalin-2018(60mg EDO) -0.446 0.188 31.2% 0.41 (0.28, 0.60] Avezum-2018(150mg DA) -1.127 0.322 19.9% 0.43 (0.28, 0.61] Avezum-2018(150mg DA) -1.127 0.322 19.9% 0.41 (0.28, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.41 (0.28, 0.61] Heterogeneity: Tau ² = 0.00; Chi ² = 7.12, df = 3 (P = 0.07); P = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 (Dardini Araction Avezum-2018(150mg DA) 0.285 0.183 30.5% 1.35 (1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.183 30.5% 1.33 (0.47, 1.13] 3.1.4 (1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.5 (Cardiovascular death Bumer-2021(RIV) -0.128 0.078 3.86% 0.88 (0.78, 1.03] Corbalin-2018(60mg EDO) -0.142 0.078 25.2% 0.88 (0.78, 1.03] Corbalin-2018(60mg EDO) -0.128 0.079 1.03] Avezum-2018(150mg DA) -0.168 0.069 14.0%, 0.89 (0.78, 1.03] Avezum-2018(150mg DA) -0.168 0.069 14.0%, 0.89 (0.78, 1.03] Avezum-2018(150mg DA) -0.168 0.069 14.0%, 0.88 (0.78,	leterogeneity: Tau ² = 0.03; Chi ² = 23.65	, df = 7 (P = 0.001)	; I ² = 70	0%		
Avezum-2018(150mg DA) -0.094 0.109 24 2% 0.91 (0.74, 1.13) Corbain-2018(60mg EDO) 0.166 0.082 26 6% 0.91 (0.74, 1.13) Corbain-2018(60mg EDO) -0.094 0.089 26 6% 0.91 (0.75, 1.08) Subtata (6% C) 0.41 Ch ² = 16.78, df = 3 (P = 0.0008); P = 82% Test for overall effect. Z = 0.86 (P = 0.39) 3.1.3 Ischemic stroke Avezum-2018(150mg DA) 0.288 0.122 24.1% 1.09 (0.86, 1.38] Avezum-2018(150mg DA) 0.038 0.09 26.6% 1.43 (120, 1.71] Corbain-2018(60mg EDO) 0.388 0.09 26.6% 1.00 (0.83, 1.21] Subtata (6% C) H = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect. Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(150mg DA) -1.109 0.37 21.0% 0.33 (0.18, 0.60] Corbain-2018(60mg EDO) -0.446 0.188 31.2% 0.64 (0.44, 0.33] Corbain-2018(60mg EDO) -0.446 0.188 31.2% 0.64 (0.44, 0.33] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.35 [0.0, 1.67] Avezum-2018(150mg DA) 0.286 0.170 1.100.% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Ch ² = 0.01, ff = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.48 (P = 0.005) 3.1.5 Averalled fiet: Z = 3.48 (P = 0.005) 3.1.7 Al-cause death Avezum-2018(150mg DA) -0.128 0.068 14.0%, 0.88 [0.76, 1.03] Corbain-2018(60mg EDO) -0.128 0.068 14.0%, 0.88 [0.78, 1.09] Avezum-2018(150mg DA) -0.128 0.068 14.0%, 0.88 [0.78, 1.09] Avezum-2018(150mg DA) -0.128 0.068 14.0%, 0.88 [0.78, 1.09] Avezum-2018(150mg DA) -0.128 0.068 14.0%, 0	Test for overall effect: Z = 1.92 (P = 0.05	5)				
Avez.m-2018(150mg DA) corbaia-2018(50mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(610mg DA) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbai	3.1.2 Stroke					
Avez.m-2018(150mg DA) corbaia-2018(50mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbaia-2018(610mg DA) corbaia-2018(60mg EDO) corbaia-2018(60mg EDO) corbai	vezum-2018(110mg DA)	-0.094	0.109	24.2%	0.91 [0.74, 1.13]	
Corbain-2018(96mg EDO) 0.068 0.089 26.0% 0.09 10.75, 10.8] Subtotal (95% CI) 0.094 0.009 26.0% 0.91 [0.75, 10.8] Subtotal (95% CG) 10.0% 0.91 [0.75, 10.8] Heterogeneity: Tau ² = 0.04; Ch ² = 16.78, df = 3 (P = 0.0008); P = 82% 3.1.3 ischemic stroke Avezum-2018(110mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(110mg DA) 0.088 0.134 23.2% 0.75 [0.56, 0.97] Corbain-2018(60mg EDO) 0.0388 0.09 26.6% 1.42 [1.20, 1.71] Corbain-2018(60mg EDO) 0.0088 26.0% 1.00 [0.83, 1.24] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau ² = 0.05; Ch ² = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.25, 0.60] Corbain-2018(60mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbain-2018(60mg EDO) -0.446 0.188 13.2% 0.46 [0.44, 0.93] Subtotal (95% CI) 100.0% 1.135 [1.09, 1.67] Avezum-2018(110mg DA) -0.07; P = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.28 0.163 30.5% 1.35 [1.09, 1.67] Avezum-2018(110mg DA) 0.28 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) -0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.28 (P = 0.01) 3.1.5 Cardiovascular death Biumer-2021(RIV) -0.128 0.068 3.6.% 0.88 [0.76, 1.03] Corbain-2018(50mg EDO) -0.128 0.068 3.6.% 0.88 [0.76, 1.03] Corbain-2018(50mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] Avezum-2018(110mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.03] Avezum-2018(110mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.03] Avez						
Corbain-2018(60m) EDO) -0.094 0.089 26.0% 0.91 [0.76, 1.08] Subtotal (95% C) 0.91 [0.72, 1.14] Heterogeneity: Tau ² = 0.04; Chi ² = 16.78, df = 3 (P = 0.0008); P = 82% Test for overall effect: Z = 0.86 (P = 0.39) 3.1.3 Ischemic stroke Avezum-2018(150mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(150mg DA) 0.088 0.134 23.2% 0.75 [0.58, 0.97] Corbain-2018(60m) EDO) 0.0388 0.09 26.6% 1.43 [120, 171] Corbain-2018(60m) EDO) 0.0388 0.09 26.6% 1.43 [120, 171] Corbain-2018(60m) EDO) 0.0388 0.09 26.6% 1.00 [0.83, 1.21] Subtotal (95% C) 0.0098 26.0% 1.00 [0.83, 1.21] Avezum-2018(150mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbain-2018(60m) EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% C) 0.0099; Chi ² = 7.12, df = 3 (P = 0.07); P = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(150mg DA) 0.23 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.23 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.28 0.078 25.2% 0.88 [0.76, 1.03] Corbain-2018(60mg EDO) -0.128 0.078 38.6% 0.08 [0.76, 1.03] Avezum-2018(150mg DA) 0.218 0.078 38.6% 0.88 [0.76, 1.03] Corbain-2018(60mg EDO) -0.128 0.068 38.6% 0.88 [0.76, 1.03] Corbain-2018(60mg EDO) -0.128 0.078 38.6% Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-201					and the second sec	
Subtal (95% C) 1000 0.91 0.21						
Heterogeneity: Tau ² = 0.04; Ch ² = 16.78, df = 3 (P = 0.0008); l ² = 82% Test for overall effect: Z = 0.86 (P = 0.39) 3.1.3 Ischemic stroke Avezum-2018(110mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(130mg EDO) 0.288 0.09 26.6% 1.00 [0.81, 1.36] Corbalian-2018(30mg EDO) 0.038 0.09 26.6% 1.00 [0.83, 1.21] Subtotal (95% Cl) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau ² = 0.06; Ch ² = 17.65, df = 3 (P = 0.0005); l ² = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(10mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalian-2018(30mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.33] Subtotal (95% Cl) Heterogeneity: Tau ² = 0.09; Ch ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Mycoardial infarction Avezum-2018(10mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(10mg DA) 0.28 0.078 25.2% 0.88 [0.76, 1.03] Heterogeneity: Tau ² = 0.00; Ch ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Biumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.078 38.6% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.069 3.1.6 Cardiovascular death Biumer-2021(RIV) -0.128 0.069 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.102 0.068 14.0% 0.87 [0.81, 0.94] 4 Heterogeneity: Tau ² = 0.00; Ch ² = 0.08; df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(100mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(100mg DA) -0.128 0.068 14.0% 0.88 [0.77, 1.01] 4 Avezum-2018(100mg ED		0.001				
3.1.3 Ischemic stroke Avezum-2018(110mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(150mg DA) 0.288 0.134 23.2% 0.75 [0.58, 0.97] Corbalian-2018(00mg EDO) 0.388 0.09 26.6% 1.43 [1.20.1.71] Corbalian-2018(00mg EDO) 0.098 26.0% 1.00 [0.83, 1.21] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneily: Tau ² = 0.06; Ch ² = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: $2 = 0.37$ (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(150mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(100mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalian-2018(00mg EDO) -0.444 0.188 31.2% 0.38 [0.25, 0.60] Corbalian-2018(00mg EDO) -0.444 0.188 31.2% 0.38 [0.25, 0.60] Corbalian-2018(100mg DA) -1.273 0.322 19.9% 0.41 [0.28, 0.60] Heterogeneily: Tau ² = 0.09; Ch ² = 7.12, df = 3 (P = 0.07); P = 58% Test for overall effect: $Z = 4.57$ (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(100mg DA) 0.285 0.163 30.5% 1.35 [1.09, 1.67] Avezum-2018(100mg DA) 0.285 0.163 30.5% 1.33 [0.77, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneily: Tau ² = 0.00; Ch ² = 0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: $Z = 3.28$ (P = 0.01) 1 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.151 0.065 36.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] 4.44 Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.01] Bahi-2020(5mg API) Kordh America 0.017 0.116 4.8% 0.290 [0.72, 1.28] Bahi-2020(5mg API) Kordh -0.128 0.068 13.6% 0.88 [0.77, 1.01] Bahi-2020(5mg API) Kordh America 0.017 0.116 4.8% 0.89 [0.72, 1.28] Bahi-2020(5mg API) Kordh -0.128 0.068 13.6% 0.88 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalian-2018(30m		, df = 3 (P = 0.0008	3); I² = 8	32%		
Avezum-2018(110mg DA) 0.086 0.122 24.1% 1.09 [0.86, 1.38] Avezum-2018(150mg DD) 0.258 0.134 23.2% 0.75 [0.58, 0.97] Corbalian-2018(60mg EDO) 0.098 26.0% 1.00 [0.83, 1.21] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau ² = 0.06; Chi ² = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(150mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalian-2018(60mg EDO) -0.442 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.442 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.442 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); I ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(150mg DA) 0.285 0.163 0.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 0.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); I ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Biumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(00mg EDO) -0.151 0.055 36.2% 0.88 [0.76, 1.03] Corbalian-2018(00mg EDO) -0.128 0.068 38.6% 0.88 [0.76, 1.03] Corbalian-2018(00mg EDO) -0.128 0.068 38.6% 0.88 [0.76, 1.03] Corbalian-2018(00mg EDO) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.76, 1.03] Corbalian-2018(150mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.76, 1.03] Corbalian-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.01] Bahi-2020(Gmg API) barbaccific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahi-2020(Gmg API) barbaccific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahi-2020(Gmg API) barbaccific -0.042 0.149 2.9% 0.88 [0.78, 0.99] Corbalian-2018(30mg EDO) -0.117 0.58 19.2% 0.89 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.58 19.2%	est for overall effect: Z = 0.86 (P = 0.39)				
Avezum-2018(150m_0 DA) -0.288 0.134 23.2% 0.75 [0.58, 0.57] Corbalán-2018(00m_0 EDO) 0.038 0.09 26.6% 1.43 [1.20, 1.71] Corbalán-2018(00m_0 EDO) 0.0098 26.0% 1.43 [1.20, 1.71] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau² = 0.06; Ch² = 17.65, df = 3 (P = 0.0005); P = 83% 783 [0.18, 0.60] Avezum-2018(110m_0 DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150m_0 DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.446 0.18 31.2% 0.64 [0.44, 0.33] Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] 0.00% 0.41 [0.28, 0.60] Heterogeneity: Tau² = 0.09; Ch² = 7.12, df = 3 (P = 0.07); l² = 58% 1.35 [1.09, 1.67] Avezum-2018(150m_0 DA) 0.28 0.13 30.5% 1.33 [0.37, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau² = 0.00; Ch² = 0.01, df = 1 (P = 0.94); l² = 0% 1.34 [0.76, 1.03] Tast for overall effect: Z = 3.28 (P = 0.001) 3.1.6 38.6% 0.88 [0.76, 1.03] Tast for overall effect: Z = 0.00; Ch² = 0.08, df = 2 (P = 0.96); l² = 0% Test for overall effect:	.1.3 Ischemic stroke					
Avezum-2018(150m_0 DA) -0.288 0.134 23.2% 0.75 [0.58, 0.57] Corbalán-2018(00m_0 EDO) 0.038 0.09 26.6% 1.43 [1.20, 1.71] Corbalán-2018(00m_0 EDO) 0.0098 26.0% 1.43 [1.20, 1.71] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau² = 0.06; Ch² = 17.65, df = 3 (P = 0.0005); P = 83% 783 [0.18, 0.60] Avezum-2018(110m_0 DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150m_0 DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.446 0.18 31.2% 0.64 [0.44, 0.33] Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] 0.00% 0.41 [0.28, 0.60] Heterogeneity: Tau² = 0.09; Ch² = 7.12, df = 3 (P = 0.07); l² = 58% 1.35 [1.09, 1.67] Avezum-2018(150m_0 DA) 0.28 0.13 30.5% 1.33 [0.37, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau² = 0.00; Ch² = 0.01, df = 1 (P = 0.94); l² = 0% 1.34 [0.76, 1.03] Tast for overall effect: Z = 3.28 (P = 0.001) 3.1.6 38.6% 0.88 [0.76, 1.03] Tast for overall effect: Z = 0.00; Ch² = 0.08, df = 2 (P = 0.96); l² = 0% Test for overall effect:	vezum-2018(110mg DA)	0.086	0.122	24.1%	1.09 [0.86, 1.38]	
Corbalia-2018(30mg EDC) 0.358 0.09 26.6%, 1.43 [1.20, 1.71] Corbalia-2018(30mg EDC) 0.098 26.0%, 1.00 [0.83, 1.21] To [0.83, 1.21] Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(110mg DA) -1.09 0.307 21.0%, 0.33 [0.18, 0.60] Avezum-2018(110mg DA) -1.109 0.307 21.0%, 0.33 [0.18, 0.60] Avezum-2018(110mg DA) -1.273 0.322 19.9%, 0.28 [0.15, 0.53] Corbalia-2018(30mg EDC) -0.446 0.188 31.2%, 0.64 [0.44, 0.33] Subtotal (95% CI) 100.0%, 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); I ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Mycardial infarction Avezum-2018(110mg DA) 0.285 0.163 30.5%, 1.35 [1.09, 1.67] Avezum-2018(110mg DA) 0.285 0.163 30.5%, 1.33 [0.97, 1.83] Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); I ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Biume-2021(RIV) -0.128 0.078 25.2%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.151 0.065 38.6%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.151 0.065 38.6%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.128 0.078 25.2%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.128 0.078 25.2%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.128 0.078 25.2%, 0.88 [0.76, 1.03] Corbalia-2018(30mg EDC) -0.128 0.068 38.6%, 0.88 [0.78, 1.00] 3.1.7 All-cause death Avezum-2018(150mg DA) -0.105 0.068 14.0%, 0.90 [0.79, 1.03] Avezum-2018(150mg AD) -0.128 0.069 13.6%, 0.88 [0.77, 1.01] Bahi-2020(Gmg API) barper -0.19 0.098 6.7%, 0.88 [0.78, 1.00] Bahi-2020(Gmg API) barper -0.19 0.098 6.7%, 0.88 [0.78, 0.99] Corbalia-2018(100mg CDC) -0.117 0.058 19.2%, 0.88 [0.78, 0.99] Corbalia-2018(30mg EDC) -0.117 0.058 19.2%, 0.88 [0.78, 0.99] Corbalia-2018(30mg EDC) -0.117 0.058 19.2%, 0.89 [0.79, 1.00] Corbalia-2018(30mg EDC)						
Corbalia-2018(60mg EDO) 0 0.098 26.0% 1.00 [0.83, 1.21] Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau' = 0.06; Chi ² = 17.65, df = 3 (P = 0.0005); l ² = 83% Test for overall effect: $Z = 0.37$ (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(150mg DA) -1.1273 0.322 19.9% 0.28 [0.15, 0.53] Corbalia-2018(30mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Heterogeneity: Tau' = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: $Z = 4.57$ (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(110mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau' = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28$ (P = 0.001) 3.1.6 Cardiovascular death Blumer-20218(30mg EDO) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalia-2018(30mg EDO) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalia-2018(30mg EDO) -0.128 0.068 38.6% 0.88 [0.76, 1.03] Corbalia-2018(30mg EDO) -0.128 0.068 38.6% 0.88 [0.76, 1.04] Heterogeneity: Tau' = 0.00; Chi ² = 0.00, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-2018(110mg DA) -0.128 0.068 14.0% Avezum-2018(150mg DA) -0.128 0.068 14.0% Bahl-2020(5mg API) North America 0.017 0.						
Subtotal (95% CI) 100.0% 1.05 [0.81, 1.36] Heterogeneity: Tau ² = 0.06; Ch ² = 17.65, df = 3 (P = 0.0005); P = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(130mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% CI) -0.042 0.223 27.9% 0.39 [0.25, 0.60] Corbalin-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% CI) -0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.28 0.163 30.5% 1.33 [0.77, 1.83] Subtotal (95% CI) -0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.151 0.065 36.2% 0.86 (0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] 4 Heterogeneity: Tau ² = 0.00; Ch ² = 0.00, df = 2 (P = 0.96); P = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 31.6% 0.88 [0.77, 1.10] Bahl:-2020(5mg API) Sais Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahl:-2020(5mg API) North America 0.017 0.116 4.8% 0.38 [0.77, 1.01] Bahl:-2020(5mg API) North America 0.017 0.116 4.8% 0.83 [0.68, 1.00] Bahl:-2020(5mg API) North America 0.017 0.116 4.8% 0.83 [0.68, 1.00] Bahl:-2020(5mg API) North America 0.017 0.116 4.8% 0.89 [0.79, 1.00] Corbalian-2018(60mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalian-2018(6						+
Heterogeneity: Tau ² = 0.06; Chi ² = 17.65, df = 3 (P = 0.0005); l ² = 83% Test for overall effect: Z = 0.37 (P = 0.71) 3.1.4 Hemorrhagic stroke Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalán-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% c1) -100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(150mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.7, 1.83] Subtotal (95% c1) -100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RW) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.121 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(30mg EDO) -0.121 0.065 36.2% 0.88 [0.76, 1.03] Fuelorogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.10] Bahi-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahi-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahi-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahi-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.09] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.78, 1.00] Corbalán-2018(60mg EDO) -0.117 0.058 19.2% 0.89 [0.78, 0.99] Corbalán-2018(60mg EDO) -0.117 0.058 19.2% 0.89 [*
Test for overall effect: $Z = 0.37 (P = 0.71)$ 3.1.4 Hemorrhagic stroke Avezum-2018(110mg DA) -1.073 0.322 19.9% 0.33 [0.18, 0.60] Avezum-2018(150mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: $Z = 4.57 (P < 0.00001)$ 3.1.5 Myocardial infraction Avezum-2018(150mg DA) 0.28 0.163 30.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.28 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28 (P = 0.01)$ 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(60mg EDO) -0.151 0.065 36.2% 0.66 [0.76, 0.98] Corbalian-2018(60mg EDO) -0.128 0.078 25.2% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; df = 2 (P = 0.96; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.008)$; l ² = 0% Test for overall effect: $Z = 3.48 (P =$, df = 3 (P = 0.0005	5); l² = 8			
Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.942 0.223 27.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% C1) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Ch ² = 7.12, df = 3 (P = 0.07); P = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.280 5.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% C1) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Ch ² = 0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.88 [0.76, 1.03] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Heterogeneity: Tau ² = 0.00; Ch ² = 0.08, df = 2 (P = 0.96); P = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.063 38.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.144 2.9% 0.93 [0.52, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.105 9.2% 0.89 [0.78, 1.03] Corbalán-2018(30mg E	est for overall effect: Z = 0.37 (P = 0.71)				
Avezum-2018(110mg DA) -1.109 0.307 21.0% 0.33 [0.18, 0.60] Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.942 0.223 27.9% 0.28 [0.15, 0.53] Corbalán-2018(30mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% C1) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Ch ² = 7.12, df = 3 (P = 0.07); P = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.280 5.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% C1) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Ch ² = 0.01, df = 1 (P = 0.94); P = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.88 [0.76, 1.03] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Heterogeneity: Tau ² = 0.00; Ch ² = 0.08, df = 2 (P = 0.96); P = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.063 38.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.144 2.9% 0.93 [0.52, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) North America 0.017 0.105 9.2% 0.89 [0.78, 1.03] Corbalán-2018(30mg E	1.4 Hemorrhagic stroke					
Avezum-2018(150mg DA) -1.273 0.322 19.9% 0.28 [0.15, 0.53] Corbalian-2018(30mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalian-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.011) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.151 0.065 36.2% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 1.03] Corbalian-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 1.04] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(150mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.88 [0.77, 1.01] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 0.88 [0.78, 0.09] Eahit-2020(5mg API) North America 0.017 0.116 4.8% 0.88 [0.78, 0.99] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.79, 1.00] Corbalian-2018(30mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) -0.00% 0.90 [0.85, 0.94]	n and a second	-1 109	0.307	21.0%	0.33 [0.18, 0.60]	
Corbalán-2018(30mg EDO) -0.942 0.223 27.9% 0.39 [0.25, 0.60] Corbalán-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% C1) 100.0% 0.41 [0.28, 0.60] Heterogeneily: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: $Z = 4.57$ (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% C1) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28$ (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(60mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% C1) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: $Z = 3.48$ (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Noth America 0.017 0.116 4.8% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.128 0.063 13.6% 0.88 [0.79, 1.00] Bahit-2020(5mg API) Noth America 0.017 0.116 4.8% 0.92 [0.83, 1.03] Corbalán-2018(30mg EDO) -0.128 0.055 12.1% 0.88 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 0.39] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 0.34]						_
Corbalån-2018(60mg EDO) -0.446 0.188 31.2% 0.64 [0.44, 0.93] Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 38.6% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 1.03] Corbalán-2018(60mg EDO) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Asia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) Asia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) Asia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) Asia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2020(5mg API) Asia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.28] Bahit-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(00mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(00mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(00mg EDO) -0.117 0.058 19.2% 0.89 [0.78, 1.00] Corbalán-2018(00mg EDO) -0.117 0.058 19.2% 0.89 [0.78, 1.00] Corbalán-2018(00mg EDO) -0.117 0.058 19.2% 0.89 [0.78, 1.00] Corbalán-2018(00mg EDO) -0.018 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.55, 0.94]						_ _
Subtotal (95% CI) 100.0% 0.41 [0.28, 0.60] Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: Z = 4.57 (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Suia Pacific -0.017 0.116 4.8% 1.02 [0.81, 1.02] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.08] Buhit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Bilumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.180 0.055 21.4% 0.92 [0.73, 1.01] Bahit-2020(5mg API) Suis Pacific -0.042 0.149 0.29% 0.96 [0.72, 1.28] Bilumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Bibutotal (95% CI) 100.0% 0.90 [0.55, 0.94]						_
Heterogeneity: Tau ² = 0.09; Chi ² = 7.12, df = 3 (P = 0.07); l ² = 58% Test for overall effect: $Z = 4.57$ (P < 0.00001) 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% Cl) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28$ (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% Cl) 100.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.068 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bhit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.03] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.03] Avezum-2018(10mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.03] Avezum-2018(10mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.018 0.55 21.4% 0.92 [0.83, 1.03] Avezum-2018(10mg EDO) -0.018 0.55 21.4% 0.92 [0.83, 1.03] Avezum-2018(10mg EDO) -0.018 0.055 21.4% 0.92 [0.83, 0.94]		-0.440	0.100			\bullet
Test for overall effect: $Z = 4.57 (P < 0.0001)$ 3.1.5 Myocardial infarction Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28 (P = 0.001)$ 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: $Z = 3.48 (P = 0.0005)$ 3.1.7 All-cause death Avezum-2018(110mg DA) -0.128 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 21.4% 0.92 [0.83, 1.03] Avezum-2018(100mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 0.94]		$df = 3 (P = 0.07) \cdot 12$	= 590/		0.41 [0.20, 0.00]	→
Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); I ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); I ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Sui Pacific -0.042 0.149 2.9% 0.88 [0.78, 0.09] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.78, 0.94]			- 50 /6			
Avezum-2018(110mg DA) 0.3 0.108 69.5% 1.35 [1.09, 1.67] Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); I ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(30mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); I ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Sui Pacific -0.042 0.149 2.9% 0.88 [0.78, 0.09] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.88 [0.78, 0.94]	1.5 Myocardial infarction					
Avezum-2018(150mg DA) 0.285 0.163 30.5% 1.33 [0.97, 1.83] Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03]		0.0	0 100	60 50/	1 25 [1 00 4 67]	
Subtotal (95% CI) 100.0% 1.34 [1.13, 1.60] Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: Z = 3.28 (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] + Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% 100.0% 0.87 [0.81, 0.94] Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(110mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Elemer-2021(RIV) -0.128 0.861 1.74 0.88 [0.78, 0.99] Corbalá						
Heterogeneilty: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.94); l ² = 0% Test for overall effect: $Z = 3.28$ (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) - 0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) - 0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) - 0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) - 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: $Z = 3.48$ (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) - 0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) - 0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific - 0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) - 0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) - 0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) - 0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) - 0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) - 0.083 0.055 21.4% 0.92 [0.83, 1.03]		0.285	0.163			
Test for overall effect: $Z = 3.28$ (P = 0.001) 3.1.6 Cardiovascular death Blumer-2021(RIV) - 0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) - 0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) - 0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) - 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); I ² = 0% Test for overall effect: $Z = 3.48$ (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) - 0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) - 0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific - 0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Surope - 0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) - 0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) - 0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) - 0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(30mg EDO) - 0.083 0.055 21.4% 0.92 [0.83, 1.03]		df = 1 (D = 0.04) 13	- 00/	100.0%	1.34 [1.13, 1.00]	•
3.1.6 Cardiovascular death Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] • Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); I² = 0% • • • Test for overall effect: Z = 3.48 (P = 0.0005) • • • • 3.1.7 All-cause death • • • • • • Avezum-2018(110mg DA) • 0.128 0.069 13.6% 0.88 [0.77, 1.01] • Bahit-2020(5mg API) Asia Pacific • 0.042 0.149 2.9% 0.96 [0.72, 1.28] • Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] • Blumer-2021(RIV) • 0.128 0.061 17.4% 0.88 [0.78, 1.00] • Corbalán-2018(60mg EDO) •			-= 0%			
Blumer-2021(RIV) -0.128 0.078 25.2% 0.88 [0.76, 1.03] Corbalán-2018(60mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Surope -0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03]						
Corbalán-2018(30mg EDO) -0.151 0.065 36.2% 0.86 [0.76, 0.98] Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.76, 0.98] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); l² = 0% 100.0% 0.87 [0.81, 0.94] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] 100.0% 3.1.7 All-cause death		-0.128	0.078	25.2%	0.88 [0.76. 1.03]	
Corbalán-2018(60mg EDO) -0.128 0.063 38.6% 0.88 [0.78, 1.00] Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); l² = 0% 0.87 [0.81, 0.94] Test for overall effect: Z = 3.48 (P = 0.0005) 33.6% 0.90 [0.79, 1.03] 3.1.7 All-cause death						-
Subtotal (95% CI) 100.0% 0.87 [0.81, 0.94] Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); I² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ●						-
Heterogeneity: Tau ² = 0.00; Chi ² = 0.08, df = 2 (P = 0.96); l ² = 0% Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Europe -0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.99 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.55 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] 4		-0.120	0.000			\blacklozenge
Test for overall effect: Z = 3.48 (P = 0.0005) 3.1.7 All-cause death Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Europe -0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] 4		$df = 2 (P = 0.96) \cdot I^2$	r = 0%			
Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Surope -0.19 0.98 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] •			070			
Avezum-2018(110mg DA) -0.105 0.068 14.0% 0.90 [0.79, 1.03] Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Surope -0.19 0.98 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] •	1 7 All-cause death					
Avezum-2018(150mg DA) -0.128 0.069 13.6% 0.88 [0.77, 1.01] Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Europe -0.19 0.98 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦		0.105	0 069	14 00/	0 00 10 70 4 021	
Bahit-2020(5mg API) Asia Pacific -0.042 0.149 2.9% 0.96 [0.72, 1.28] Bahit-2020(5mg API) Europe -0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						
Bahit-2020(5mg API) Europe -0.19 0.098 6.7% 0.83 [0.68, 1.00] Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.052 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						
Bahit-2020(5mg API) North America 0.017 0.116 4.8% 1.02 [0.81, 1.28] Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						
Blumer-2021(RIV) -0.128 0.061 17.4% 0.88 [0.78, 0.99] Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						
Corbalán-2018(30mg EDO) -0.117 0.058 19.2% 0.89 [0.79, 1.00] Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						-
Corbalán-2018(60mg EDO) -0.083 0.055 21.4% 0.92 [0.83, 1.03] Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94] ♦						
Subtotal (95% CI) 100.0% 0.90 [0.85, 0.94]						
		-0.083	0.055			
				100.0%	0.90 [0.85, 0.94]	•
Heterogeneity: Tau ² = 0.00; Chi ² = 2.48, df = 7 (P = 0.93); l ² = 0% Test for overall effect: Z = 4.24 (P < 0.0001)			2 = 0%			
Test for overall effect. Z = 4.24 (F < 0.0001)	e_{3} ($P < 0.00$					
					-	0.2 0.5 1 2 5
DOACs Warfarin						

anticoagulants; DA, dabigatran; API, apixaban; EDO, edoxaban; RIV, rivaroxaban; SSE, stroke or systemic embolism; CI, confidence interval.

compared with warfarin, the use of DOACs was associated with reduced risks of major or NMCR bleeding (HR = 0.70; 95%CI.57–0.86), major bleeding (HR = 0.70; 95%CI.53–0.92),

ICH (HR = 0.42; 95% CI.24–0.74), and any bleeding (HR = 0.70; 95%CI.62–0.78), but not gastrointestinal bleeding (HR = 1.08; 95% CI.65–1.78).

				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.1.1 Major or NMCR bleeding					
Bahit-2020(5mg API) Asia Pacific	-0.707	0.131	14.3%	0.49 [0.38, 0.64]	
Bahit-2020(5mg API) Europe	-0.308	0.09	16.2%	0.73 [0.62, 0.88]	
Bahit-2020(5mg API) North America	-0.252	0.096	15.9%	0.78 [0.64, 0.94]	
Blumer-2021(RIV)	0.068	0.04	17.9%	1.07 [0.99, 1.16]	-
Corbalán-2018(30mg EDO)	-0.462	0.041	17.8%	0.63 [0.58, 0.68]	• I
Corbalan-2018(60mg EDO)	-0.139	0.038	17.9%	0.87 [0.81, 0.94]	
Subtotal (95% CI)			100.0%	0.75 [0.61, 0.92]	◆
Heterogeneity: Tau ² = 0.06; Chi ² = 105	5.00, df = 5 (P < 0.000	01); P	= 95%		
Test for overall effect: Z = 2.70 (P = 0.	007)	,.			
1.1.2 Major bleeding					
Avezum-2018(110mg DA)	-0.211	0.076	13.4%	0.81 [0.70, 0.94]	
Avezum-2018(150mg DA)	-0.062			0.94 [0.81, 1.08]	
Bahit-2020(5mg API) Asia Pacific	-0.642		9.9%	0.53 [0.37, 0.74]	
Bahit-2020(5mg API) Europe	-0.233		11.6%	0.79 [0.62, 1.02]	
Sahit-2020(5mg API) North America	+0.256		11.6%	0.77 [0.60, 1.00]	<u> </u>
Blumer-2021(RIV)	0.058		13.3%	1.06 [0.91, 1.23]	- - [
Corbalán-2018(30mg EDO)	-0.734		13.2%	0.48 [0.41, 0.56]	
Corbalán-2018(60mg EDO)	-0.198	0.072	13.5%	0.82 [0.71, 0.94]	
Subtotal (95% CI)			100.0%	0.76 [0.63, 0.92]	•
Heterogeneity: Tau ² = 0.07; Chi ² = 64. Test for overall effect: Z = 2.79 (P = 0.	• • • • • • • • • • • • • • • • • • • •	1); P =	89%		
$\frac{1}{2} = \frac{1}{2} = \frac{1}$	000)				
1.1.3 Intracranial hemorrhage					
Avezum-2018(110mg DA)	-1.204		12.6%	0.30 [0.19, 0.47]	
Avezum-2018(150mg DA)	-0.821		15.6%	0.44 [0.30, 0.64]	
3ahit-2020(5mg API) Asia Pacific	-1.1	0.299	8.8%	0.33 [0.19, 0.60]	
Bahit-2020(5mg API) Europe	-0.816	0.311	8.3%	0.44 [0.24, 0.81]	
Bahit-2020(5mg API) North America	-0.842	0.398	5.6%	0.43 [0.20, 0.94]	
Blumer-2021(RIV)	-0.462	0.191	15.7%	0.63 [0.43, 0.92]	
Corbalán-2018(30mg EDO)	-1.171	0.2	15.0%	0.31 [0.21, 0.46]	
Corbalán-2018(60mg EDO)	-0.654	0.163		0.52 [0.38, 0.72]	
Subtotal (95% CI)			100.0%	0.42 [0.35, 0.52]	●
Heterogeneity: Tau ² = 0.03; Chi ² = 11.	21, df = 7 (P = 0.13); l	2 = 38%	6		
Test for overall effect: $Z = 8.37$ (P < 0.	00001)				
4.1.4 Gastrointestinal bleeding					
Avezum-2018(110mg DA)	0.086	0.127	24.5%	1.09 [0.85, 1.40]	
Avezum-2018(150mg DA)	0.372			1.45 [1.15, 1.83]	 − ∎ −
Corbalán-2018(30mg EDO)	-0.416			0.66 [0.52, 0.84]	
Corbalán-2018(60mg EDO)	0.199			1.22 [0.99, 1.50]	⊢ ∎
Subtotal (95% CI)			100.0%	1.06 [0.77, 1.47]	
Heterogeneity: Tau ² = 0.10; Chi ² = 23.	80, df = 3 (P < 0.0001); l² = 8		• • • • • • • • • • • • • • • • • • • •	l l
Test for overall effect: Z = 0.37 (P = 0.					
1.1.5 Any bleeding					
, ,	0.000	0.022	25.10	0 70 10 74 0 941	•
Avezum-2018(110mg DA)	-0.236			0.79 [0.74, 0.84]	-
Avezum-2018(150mg DA)	-0.094			0.91 [0.86, 0.97]	• 1
Corbalán-2018(30mg EDO)		0.038		0.67 [0.62, 0.72]	- .
Corbalán-2018(60mg EDO) Subtotal (95% CI)	-0.128	0.032	25.1% 100.0%	0.88 [0.83, 0.94] 0.81 [0.71, 0.92]	▲
Heterogeneity: Tau ² = 0.02; Chi ² = 45.	71, df = 3 (P < 0.0000	1); l² =			
Test for overall effect: Z = 3.30 (P = 0.					
					0.2 0.5 1 2 5
					DOACs Warfarin

FIGURE 4 | Adjusted safety date of direct oral anticoagulants compared with warfarin in non-Latin patients with atrial fibrillation. DOACs, direct oral anticoagulants; DA, dabigatran; API, apixaban; EDO, edoxaban; RIV, rivaroxaban; CI, confidence interval.

For patients treated with anticoagulants in non-Latin American patients with AF, for the effectiveness outcomes in Figure 3, the use of DOACs compared with warfarin was significantly associated with decreased risks of SSE (HR = 0.87; 95%CI.75-1.00), hemorrhagic stroke (HR = 0.41; 95%CI.28-0.60), cardiovascular death (HR = 0.87; 95% CI.81-0.94), allcause death (HR = 0.90; 95%CI.85–0.94), conversely, increasing the risk of myocardial infarction (HR = 1.34; 95%CI 1.13-1.60), but not stroke (HR = 0.91; 95%CI.72–1.14) and ischemic stroke (HR = 1.05; 95% CI.81–1.36). For the safety outcomes in Figure 4, compared with warfarin use, the use of DOACs was associated with reduced risks of major or NMCR bleeding (HR = 0.75; 95% CI.61-0.92), major bleeding (HR = 0.76; 95% CI.63-0.92), ICH (HR = 0.42; 95% CI.36-0.52) and any bleeding (HR = 0.81; 95%CI.71–0.92), but not gastrointestinal bleeding (HR = 1.06; 95%CI.77-1.47). Not only that, we also conducted a summary analysis of the adjusted data of outcomes between Latin American patients and non-Latin American patients in Figure 5. The P-interaction between Latin American patients and non-Latin American patients with AF was no significant difference.

Publication Bias

We have not performed an analysis of publication bias due to only 4 studies were included in our meta-analysis. It was noted that the publication bias should not be evaluated for some reported outcomes when fewer than 10 studies were included.

DISCUSSION

The main findings of our study were as follows: (1) DOAC use resulted in lower rates of SSE, stroke, hemorrhagic stroke, allcause death, and associated with safer profiles (lower major or NMCR bleeding, major bleeding, ICH, and any bleeding) than warfarin in Latin American patients with AF; (2) DOAC use resulted in lower rates of SSE, hemorrhagic stroke, all-cause death, cardiovascular death, and associated with safer profiles (lower major or NMCR bleeding, major bleeding, ICH, and any bleeding) than warfarin in non-Latin American patients with AF; (3) DOAC use increased the risk of myocardial infarction than warfarin in non-Latin American patients with AF, but not in Latin American patients with AF; (4) in comparison to VKAs, DOACs were non-inferior regarding the outcomes of ischemic stroke, cardiovascular death, and gastrointestinal bleeding in Latin American patients with AF and the outcomes of stroke, ischemic stroke, and gastrointestinal bleeding in non- Latin American patients.

Important differences in clinical characteristics, response to treatment, and outcomes of patients with AF exist in the diverse regions of the world. Previous studies have shown that Latin American patients with AF are suffering from higher risks of death and embolism than non-Latin American patients with AF (20, 21). Actually, there are many reasons for the increased risk of death and embolism in Latin American patients with AF. Life expectancy differed substantially across cities within the same country. Cause-specific mortality also varied across cities, with some causes of death (unintentional and violent injuries and deaths) showing large variation within countries, whereas other causes of death (communicable, maternal, neonatal and nutritional, cancer, cardiovascular disease, and other non-communicable diseases) varied substantially between countries. These results highlight considerable heterogeneity in life expectancy and causes of death across cities of Latin America (22). Moreover, heterogeneity of risk factors (23-25) and socioeconomic conditions, public awareness, and availability of healthcare services that influence outcomes of diseases differ substantially between countries (26, 27) in Latin America and still need to be taken into account. Furthermore, inadequate prescription for medications associated with death reduction might also affect the prognosis of Latin American patients with AF (14). Therefore, antithrombotic therapy is particularly important to reduce the risk of embolism in Latin American patients with AF. Previous meta-analyses including the posthoc analyses and sub-analyses of DOAC RCTs showed that there is a non-inferiority of DOACs compared with warfarin in Latin American patients with AF (15). Compared to the previous study, the RCTs included in this meta-analysis are outdated. More importantly, the number of available clinical studies are small and the results are controversial. In recent years, several new post-hoc analyses of RCTs not only examined the association between region and efficacy and safety outcomes but also explored the use of individual DOACs compared with warfarin in Latin American patients. The RCTs provide more endpoint events and arrive at different conclusions. Therefore, we aimed to reassess the effectiveness and safety outcomes of DOACs vs. warfarin in Latin American and non-Latin American patients with AF. Our meta-analysis shows that DOACs appeared to have significant reductions in SSE, stroke, hemorrhagic stroke, all-cause death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, but showed comparable rates of ischemic stroke, cardiovascular death, and gastrointestinal bleeding in Latin American patients with AF. DOACs appeared to have significant reductions in SSE, hemorrhagic stroke, all-cause death, cardiovascular death, major or NMCR bleeding, major bleeding, ICH, and any bleeding and increased the risk of myocardial infarction, but comparable risks of stroke, ischemic stroke, and gastrointestinal bleeding in non-Latin American patients with AF. In addition, we assessed crude event rates of outcomes between DOACs vs. warfarin in Latin/non-Latin American patients with AF. Overall, in comparison to warfarin, DOACs had lower or similar rates of thromboembolic and bleeding risk, which was consistent with a previous study (15). Interestingly, we found that DOACs increased the risk of myocardial infarction compared with warfarin in non-Latin American patients with AF. The result was derived from the RE-LY study, which included patients using dabigatran. Previous studies have warned this risk (28, 29). Prospective data on dabigatran in this population undergoing PCI are still needed.

It is worth pointing out that DOACs have advantages over warfarin such as short onset time, short half-life, low interand intra-individual variability, and drug-drug interactions. The current international guidelines recommend the use of DOACs as replacement therapy for VKAs in patients with non-valvular AF because it has more effective, safer, and more convenient features. Different from DOACs, the anticoagulant activity of

Subgroup	NO.of patients	DOACs	Warfarin	Pooled HR (95% CI)		I ² value	P-value	P-interaction
		NO.of events (%)						
SSE								
LA	8965	117(3.47)	159(4.11)	۲∎⊸ı	0.78 (0.64-0.96)	0%	0.02	0.43
NLA	62716	1282(3.43)	951(3.74)	⊢≣ -	0.87 (0.75-1.00)	70%	0.43	
Stroke								
LA	3617	888(3.65)	57(4.73)	⊢∎	0.75 (0.57-0.99)	0%	0.05	0.31
NLA	35601	846(3.56)	446(3.76)	⊨∎⊸	0.91(0.72-1.14)	82%	0.39	
Ischemic stroke	•							
LA	3617	83(3.43)	35(2.90)	F	1.14 (0.83-1.58)	0%	0.41	0.69
NLA	35601	741(3.12)	334(2.81)	⊢ ∎1	1.05(0.81-1.36)	83%	0.71	
Hemorrhagic st	troke							
LA	3617	5(0.20)	21(1.74)	H B	0.14(0.05-0.36)	0%	0.0001	0.04
NLA	35601	100(0.42)	114(0.96)	⊢∎⊷	0.41(0.28-0.60)	58%	0.00001	
Myocardial inf:	arction							
LA	636	2(0.62)	2(0.63)	⊢ ∎	- 0.97(0.14-6.90)			0.74
NLA	17157	174(1.52)	64(1.12)		1.34(1.13-1.60)	0%	0.001	
All-cause death								
LA	8965	621(12.18)	489(12.63)	× = -	0.89 (0.80-1.00)	8%	0.05	0.94
NLA	62716	2958(7.92)	2138(8.41)		0.90 (0.85-0.94)	0%	0.001	
Cardiovascular	death							
LA	4541	267(9.84)	176(9.62)	ب ر	0.92 (0.68-1.26)	70%	0.62	0.73
NLA	30826	1165(6.30)	836(6.77)	-	0.87(0.81-0.94)	0%	0.0005	
Major or NMC	R bleeding							
LA	8943	579(12.99)	739(12.47)	H	0.70 (0.57-0.86)	71%	0.0005	0.64
NLA	45558	4198(16.23)	3515(17.84)	⊢∎⊣	0.75 (0.61-0.92)	95%	0.007	
Major bleeding								
LA	8965	211(4.14)	219(5.44)	H B 1	0.70(0.53-0.92)	0.54	0.01	0.62
NLA	62716	769(2.06)	905(3.56)	⊢∎⊷	0.76(0.63-0.92)	89%	0.0005	
Intracranial he	morrhage							
LA	8965	38(0.74)	65(1.68)	H -	0.42 (0.24-0.74)	48%	0.003	0.97
NLA	62716	236(0.63)	363(1.43)	-	0.42 (0.35-0.52)	38%	< 0.00001	
Gastrointestina	l bleeding							
LA	3617	30(1.24)	29(2.40)	ب	1.08 (0.65-1.78)	41%	0.77	0.96
NLA	35601	516(2.17)	285(2.40)	,,	1.06(0.77-1.47)	87%	0.71	
Any bleeding								
LA	3617	536(22.21)	362(30.06)	-	0.70 (0.62-0.78)	0%	0.00001	0.08
NLA	35601	5577(23.48)	3918(33.05)	H	0.81(0.71-0.92)	93%	0.001	
				0 0.5 1 1.5	2			
				A 10				

FIGURE 5 | Efficacy and safety outcomes in AF patients from Latin American and non-Latin American. SSE, stroke or systemic embolism; CI, confidence interval; HR, hazard ratio; LA, Latin American; NLA, non-Latin American; CI, confidence interval; major or NMCR bleeding, major or non-major clinically relevant bleeding.

VKAs depends on TTR (time in therapeutic range). Among the included studies, the mean TTR of VKAs users in Latin America ranged from 58 to 66%, which was not higher than that of non-Latin Americans overall and lower than what is recommended in the guidelines (1, 30). Therefore, DOACs may be regarded as a safer alternative to VKAs in Latin American patients with AF. Although no observational studies have been carried out to directly compare the use of DOACs and warfarin in Latin American patients with AF, several studies have validated the benefits of the use of DOACs in this population. Data from the GLORIA-AF (Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation, Phase II) study indicated the consistent safety and effectiveness of dabigatran in Latin American patients with AF during a 2-years follow-up (31). Moreover, the XANTUS-EL (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Eastern Europe, the Middle East and Africa [EEMEA], and Latin America) study confirmed the benefits of rivaroxaban for stroke prevention in patients with non-valvular AF from Eastern Europe, the Middle East, Africa, and Latin America (32). However, the results concerning whether DOACs are more cost-effective than warfarin in Latin America remain a controversy (33). The evidence provided by our metaanalysis may offer some confidence to clinicians when selecting DOACs for Latin American patients who need anticoagulation therapy, especially for those at a high risk of bleeding. The present results support that the use of DOACs is at least non-inferior to warfarin in Latin American patients with AF and provides an effective anticoagulant choice without monitoring. Further studies should be performed to clarify this problem.

Limitations

Several limitations should be acknowledged. First, because of the small number of included studies, we did not perform subgroup analysis based on dosage or type of DOACs. Second, individual patient-level data from trials were not available, and some of the patients in Latin American countries enrolled might not be ethnically Latin American. Third, the results of the present analysis do not represent all countries in Latin America, as

REFERENCES

- 1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS): the task force for the diagnosis management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC. *Eur Heart J.* (2021) 42:373–498. doi: 10.1093/eurheartj/ehaa612
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. *Int J Stroke*. (2021) 16:217–21. doi: 10.1177/1747493019897870
- Chu G, Versteeg HH, Verschoor AJ, Trines SA, Hemels M, Ay C, et al. Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology. *Blood Rev.* (2019) 35:59–67. doi: 10.1016/j.blre.2019.03.005
- Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. *Blood Adv.* (2018) 2:200–9. doi: 10.1182/bloodadvances.2017010694

a limited number of countries in this region were included. Finally, we cannot exclude the possibility that there is potential confounding or interaction between enrollment in Latin America and anticoagulants.

CONCLUSION

The current pooled data from the four *post-hoc* analyses of RCTs suggested that compared with warfarin, DOACs appeared to have significant reductions in SSE, stroke, hemorrhagic stroke, all-cause death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, but comparable risks of ischemic stroke, cardiovascular death, and gastrointestinal bleeding in Latin American patients with AF. DOACs appeared to have significant reductions in SSE, hemorrhagic stroke, all-cause death, cardiovascular death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, and increased the risk of myocardial infarction, but comparable risks of stroke, ischemic stroke, and gastrointestinal bleeding in non-Latin American patients with AF.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm. 2022.841341/full#supplementary-material

- Kim K, Lee Y, Kim T, Uhm J, Pak H, Lee M, et al. Effect of nonvitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. *Korean Circ J.* (2018) 48:406. doi: 10.4070/kcj.201 7.0328
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* (2011) 365:981–92. doi: 10.1056/NEJMoa1107039
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JJ, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. *Heart Rhythm.* (2019) 16:e66–93. doi: 10.1016/j.hrthm.2019.01.024
- 8. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* (2016) 37:2893–962. doi: 10.1093/eurheartj/ehw210
- 9. Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with

acute venous thromboembolism. *Pharmacotherapy*. (2020) 40:204–10. doi: 10.1002/phar.2369

- Cheung C, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. *Ann Pharmacother*. (2021) 55:711–22. doi: 10.1177/1060028020967635
- Jerjes-Sanchez C, Corbalan R, Barretto A, Luciardi HL, Allu J, Illingworth L, et al. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. *Clin Cardiol.* (2019) 42:553–60. doi: 10.1002/clc.23176
- Koziel M, Teutsch C, Bayer V, Lu S, Gurusamy VK, Halperin JL, et al. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. J Arrhythm. (2021) 37:990–1006. doi: 10.1002/joa3.12588
- Cantu-Brito C, Silva GS, Ameriso SF. Use of guidelines for reducing stroke risk in patients with nonvalvular atrial fibrillation: a review from a latin american perspective. *Clin Appl Thromb Hemost.* (2018) 24:22–32. doi: 10.1177/1076029617734309
- Corbalan R, Nicolau JC, Lopez-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, et al. Edoxaban versus warfarin in latin american patients with atrial fibrillation: the ENGAGE AF-TIMI 48 trial. *J Am Coll Cardiol.* (2018) 72:1466–75. doi: 10.1016/j.jacc.2018.07.037
- Su Z, Zhang H, He W, Ma J, Zeng J, Jiang X. Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation. *Medicine*. (2020) 99:e19542. doi: 10.1097/MD.000000000019542
- Xue Z, Zhang H. Non-Vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies. *Stroke.* (2019) 50:2819–28. doi: 10.1161/STROKEAHA.119.026054
- Bahit MC, Granger CB, Alexander JH, Mulder H, Wojdyla DM, Hanna M, et al. Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: findings from the ARISTOTLE trial. *Int J Cardiol.* (2020) 302:53–8. doi: 10.1016/j.ijcard.2019.12.060
- Blumer V, Rivera M, Corbalan R, Becker RC, Berkowitz SD, Breithardt G, et al. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. Am Heart J. (2021) 236:4–12. doi: 10.1016/j.ahj.2021.02.004
- Avezum A, Oliveira G, Diaz R, Hermosillo J, Oldgren J, Ripoll EF, et al. Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. *Open Heart*. (2018) 5:e800. doi: 10.1136/openhrt-2018-000800
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* (2011) 365:883–91. doi: 10.1056/NEJMoa1009638
- Massaro AR, Lip G. Stroke prevention in atrial fibrillation: focus on Latin America. Arq Bras Cardiol. (2016) 107:576–89. doi: 10.5935/abc.20160116
- Bilal U, Hessel P, Perez-Ferrer C, Michael YL, Alfaro T, Tenorio-Mucha J, et al. Life expectancy and mortality in 363 cities of Latin America. *Nat Med.* (2021) 27:463–70. doi: 10.1038/s41591-020-01214-4
- Rivera-Andrade A, Luna MA. Trends and heterogeneity of cardiovascular disease and risk factors across Latin American and Caribbean countries. *Prog Cardiovasc Dis.* (2014) 57:276–85. doi: 10.1016/j.pcad.2014.09.004
- Miranda JJ, Herrera VM, Chirinos JA, Gomez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American consortium of studies in obesity (LASO). *PLoS ONE*. (2013) 8:e54056. doi: 10.1371/journal.pone.0054056

- Champagne BM, Sebrie EM, Schargrodsky H, Pramparo P, Boissonnet C, Wilson E. Tobacco smoking in seven Latin American cities: the CARMELA study. *Tob Control.* (2010) 19:457–62. doi: 10.1136/tc.2009.0 31666
- Ouriques MS, Sacks C, Hacke W, Brainin M, de Assis FF, Marques PO, et al. Priorities to reduce the burden of stroke in Latin American countries. *Lancet Neurol.* (2019) 18:674–83. doi: 10.1016/S1474-4422(19)3 0068-7
- Avezum A, Costa-Filho FF, Pieri A, Martins SO, Marin-Neto JA. Stroke in Latin America: burden of disease and opportunities for prevention. *Glob Heart.* (2015) 10:323–31. doi: 10.1016/j.gheart.201 4.01.006
- Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. *Arch Intern Med.* (2012) 172:397–402. doi: 10.1001/archinternmed.201 1.1666
- Gaubert M, Resseguier N, Laine M, Bonello L, Camoin-Jau L, Paganelli F. Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. *J Thromb Haemost.* (2018) 16:465–73. doi: 10.1111/jt h.13931
- Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest.* (2018) 154:1121–201. doi: 10.1016/j.chest.201 8.07.040
- 31. Dubner S, Saraiva JFK, Fragoso JCN, Barón-Esquivias G, Teutsch C, Gurusamy VK, et al. Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: two years follow up results from GLORIA-AF registry. *Int J Cardiol Heart Vasc.* (2020) 31:100666. doi: 10.1016/j.ijcha.2020.100666
- 32. Martínez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL. et al. XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. *Egypt Heart J.* (2018) 70:307–13. doi: 10.1016/j.ehj.2018.09.002
- Lopes RD, Berger SE, Di Fusco M, Kang A, Russ C, Afriyie A. et al. A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. *Int J Cardiol.* (2020) 319:85– 93. doi: 10.1016/j.ijcard.2020.06.061

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Wang, Luo, Huang, Zhu, Yin and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.